%PDF-1.3
%
3 0 obj
<>>>/BBox[0 0 612 792]/Length 158>>stream
xα0OqUPǀ?)E
VN(h$
F3
QzǶ>n77K%/[6_!<]JSM!NK-*O<ՅD~| &q68@ȝS{6,
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 158>>stream
xα0OqUPǀ?)E
VN(h$
F3
QzǶ>n77K%/[6_!<]JSM!NK-*O<ՅD~| &q68@ȝS{6,
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 158>>stream
xα0OqUPǀ?)E
VN(h$
F3
QzǶ>n77K%/[6_!<]JSM!NK-*O<ՅD~| &q68@ȝS{6,
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 158>>stream
xα0OqUPǀ?)E
VN(h$
F3
QzǶ>n77K%/[6_!<]JSM!NK-*O<ՅD~| &q68@ȝS{6,
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 158>>stream
xα0OqUPǀ?)E
VN(h$
F3
QzǶ>n77K%/[6_!<]JSM!NK-*O<ՅD~| &q68@ȝS{6,
endstream
endobj
10 0 obj
<>>>/BBox[0 0 612 792]/Length 158>>stream
xα0OqUPǀ?)E
VN(h$
F3
QzǶ>n77K%/[6_!<]JSM!NK-*O<ՅD~| &q68@ȝS{6,
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 158>>stream
xα0OqUPǀ?)E
VN(h$
F3
QzǶ>n77K%/[6_!<]JSM!NK-*O<ՅD~| &q68@ȝS{6,
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 158>>stream
xα0OqUPǀ?)E
VN(h$
F3
QzǶ>n77K%/[6_!<]JSM!NK-*O<ՅD~| &q68@ȝS{6,
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 158>>stream
xα0OqUPǀ?)E
VN(h$
F3
QzǶ>n77K%/[6_!<]JSM!NK-*O<ՅD~| &q68@ȝS{6,
endstream
endobj
12 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2018-03-23T01:34:20-07:00
2018-03-14T00:27:37+05:30
application/pdf
THY-2017-0430-ver9-Sabini_3P 386..394
uuid:df031fec-2840-411c-a60e-de62188867dc
uuid:7866c2fa-772a-477a-a300-b928329ee666
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
19 0 obj
<>stream
x+ |
endstream
endobj
20 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
21 0 obj
<>stream
x+ |
endstream
endobj
22 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
23 0 obj
<>stream
x+ |
endstream
endobj
24 0 obj
<>stream
xS**T0T0 Bi yw*
endstream
endobj
25 0 obj
<>stream
x+ |
endstream
endobj
26 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
27 0 obj
<>stream
x+ |
endstream
endobj
28 0 obj
<>stream
xS**T0T0 Bi y+
endstream
endobj
29 0 obj
<>stream
x+ |
endstream
endobj
30 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
32 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 59.7543 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(of)-342(statins)-337.2(\(17,18\),)-341.7(as)-337.2(GO)-338(is)-336.2(notoriously)-340.6(identied)-340.8(as)-337.2(an)-337.4(au-)]TJ
0 -1.1174 TD
[(toimmune)-318(inammatory)-322.2(condition)-316.7(\(19\).)-318.8(Thus,)-314.1(its)-314.4(pathogen-)]TJ
0 -1.1116 TD
[(esis)-235.7(is)-226.8(believed)-231.4(to)-232.7(involve)-228(an)-228(autoimmune)-234.9(aggression)-231.9(against)]TJ
T*
[(autoantigens)-431.6(expressed)-433.4(by)-422.7(both)-425(the)-425.1(thyroi)-6.8(d)-421.6(and)-424.9(orbital)-429.7(-)]TJ
T*
[(broadipose)-456.7(tissues,)-449.7(leading)-453.8(to)-445.8(the)-453.8(activation)-452.8(of)-445.7(secondary)]TJ
0 -1.1174 TD
[(mechanisms)-540.8(that)-541.5(involve)-539(mediators)-537.6(of)-537.8(inammation)-535.5(and)]TJ
0 -1.1116 TD
[(oxidative)-283.3(stress)-283.7(\(19,20\).)]TJ
1.0137 -1.1116 TD
[(Statins)-343(are)-339.7(commonly)-340.9(employed)-340.8(for)-337.3(the)-338.7(treatment)-343.3(of)-336.2(hy-)]TJ
-1.0137 -1.1174 TD
[(percholesterolemia,)-319.7(a)-307.5(condition)-305.2(for)-308.5(which)-312.9(they)-305.2(are)-310.9(quite)-306.4(ef-)]TJ
0 -1.1116 TD
[(fective)-437.6(\(21\).)-434(They)-433(may)-431.9(show)-437.1(adverse)-431.4(reactions,)-437.3(and)-436.4(have)]TJ
T*
[(been)-191(postulated)-192.1(to)-192.4(increase)-191.9(the)-188.9(risk)-188.6(of)-192.2(glucocorticoid-induced)]TJ
0 -1.1174 TD
[(hepatitis)-421.5(in)-417(GO)-412.9(patients,)-417.9(although)-419.2(a)-417(population)-415.8(study)-414.4(was)]TJ
0 -1.1116 TD
[(sufciently)-244.8(reassuring)-237.6(\(22\).)-238.2(The)-236.1(possibility)-242.8(that)-236.2(the)-235(observed)]TJ
T*
[()50.8(prote)-7.8(ctive)48.4()-289(effect)-292.4(of)-290.1(statins)-291.1(on)-284.4(GO)-291.9(development)-293.6(may)-287.9(be)-291.3(a)]TJ
T*
[(consequence)-415.2(of)-405.3(their)-410.1(hypolipemic)-407.7(actions)-407.5(was)-408.3(not)-406.6(consid-)]TJ
0 -1.1174 TD
[(ered,)-275.1(presumably)-273.7(due)-269.4(to)-267.3(the)-275.3(lack)-271.8(of)-267.1(association)-274.8(between)-271.4(GO)]TJ
0 -1.1116 TD
[(and)-482.5(treatment)-487.3(with)-483.6(non-statin)-478.9(lipid-)-7(lowering)-483.4(medications,)]TJ
T*
[(which)-353.3(was)-350.7(also)-351.1(assessed)-357.1(in)-347.9(the)-350.2(study)-351(of)-353.5(Stein)]TJ
/F5 1 Tf
19.2259 0 TD
[(et)-349.1(al)]TJ
/F4 1 Tf
1.8604 0 TD
[(.,)-346.7(to)-347.9(the)]TJ
-21.0863 -1.1174 TD
[(authors)-297.8(knowledge)-301.2(the)-292.6(only)-292.5(invest)-7.8(igation)-291.5(conducted)-301.5(on)-290.2(the)]TJ
0 -1.1116 TD
[(subject)-252(\(17\).)-249.7(However,)-251.3(high)-246.4(cholesterol)-251.9(levels)-245.1(are)-253.3(associated)]TJ
T*
[(with)-431.7(a)-428.5(general,)-435.2(altered,)-429.6(inammatory)-431.7(state)-434.1(\(23,24\),)-428.1(which)]TJ
0 -1.1174 TD
[(may)-236.1(be)-233.7(responsible)-238.9(for)-233.6(the)-235(observation)-239.1(of)-232.6(Stein)]TJ
/F5 1 Tf
19.0819 0 TD
[(et)-233.9(al)]TJ
/F4 1 Tf
1.7452 0 TD
[(.)-233.8(\(17\).)-232.4(In)]TJ
-20.8271 -1.1116 TD
[(this)-298.2(regard,)-300.3(the)-292.6(absence)-300.2(of)-295.9(a)-296(signicant)-301.4(association)-297.8(between)]TJ
T*
[(GO)-395.6(and)-390.4(lipid-lowering)-392.4(medications)-391.4(other)-392.7(than)-391.6(statins)-394.8(may)]TJ
0 -1.1174 TD
[(be)-268.3(explained)-267.1(by)-267.1(the)-263.8(fact)-266(that)-265(these)-267(medications)-270.5(have)-265.9(a)-267.2(lower)]TJ
0 -1.1116 TD
[(potency)-315.4(in)-307.6(comparison)-314(to)-307.6(statins)-314.1(\(25\).)-307.3(It)-313.3(must)-310.8(also)-310.8(be)-308.6(taken)]TJ
T*
[(into)-269.6(account)-276.3(that,)-268.4(although)-275.2(remarkable,)-273.8(the)-269.5(study)-270.4(from)-270.5(Stein)]TJ
/F5 1 Tf
T*
[(et)-199.3(al)]TJ
/F4 1 Tf
1.7106 0 TD
[(.)-193.5(may)-195.8(possess)-198.2(some)-196.7(of)-198(the)-194.7(typical)-200.5(limitations)-199.4(attributed)-198.1(to)]TJ
-1.7106 -1.1174 TD
[(retrospective)-312.8(investigations,)-303.7(as)-308.4(well)-306.2(as)-302.7(the)-304.1(fact)-306.3(that)-305.3(the)-304.1(data)]TJ
0 -1.1116 TD
[(utilized)-345.7(were)-341.6(derived)-338.4(from)-339.6(a)-336.3(datab)-8(ase)-339.5(and)-338.5(that)-339.9(comprehen-)]TJ
T*
[(sive)-253.2(clinical)-254.7(data)-254.5(of)-249.8(the)-246.5(patients)-253.2(included)-253.3(were)-255.2(not)-251.1(examined)]TJ
0 -1.1174 TD
[(\(17\).)-261.2(However,)-257.1(if,)-259.2(in)-255.8(contrast)-264.6(with)-253.2(the)-258(interpretation)-267.2(of)-255.6(Stein)]TJ
/F5 1 Tf
0 -1.1116 TD
[(et)-354.8(al)]TJ
/F4 1 Tf
1.8604 0 TD
[(.)-354.8(\(17\),)-347.6(the)-350.2(effect)-355.7(of)-353.5(statins)-348.7(on)-353.5(GO)-349.5(development)-356.9(in)-347.9(GD)]TJ
-1.8604 -1.1116 TD
[(patients)-426(reected)-428.1(their)-421.6(hypolipemic)-425(actions,)-422.5(a)-422.7(relation)-420.4(be-)]TJ
0 -1.1174 TD
[(tween)-262.3(high)-258(serum)-261.1(cholesterol)-263.4(and)-257.9(the)-263.8(presence)-260.9(of)-255.6(GO)-263.1(in)-255.8(GD)]TJ
0 -1.1116 TD
[(patients)-466.3(would)-455.8(be)-458.4(expected.)-466.3(In)-457.2(addition,)-457.3(the)-459.6(severity)-460.4(and)]TJ
T*
[(activity)-276.6(of)-267.1(GO)-274.6(may)-270.6(differ)-272.7(based)-266.8(on)-272.9(the)-269.5(cholesterol)-275(levels.)-271.6(In)]TJ
T*
[(order)-196.7(to)-198.2(investigate)-200.2(these)-197.8(possibilities,)-197.7(a)-192.3(cross-sectional)-205.2(study)]TJ
0 -1.1174 TD
[(was)-419.8(conducted)-416.7(in)-411.3(consecutive)-420(patients)-420.3(with)-414.5(GD,)-416.3(aimed)-412.4(at)]TJ
0 -1.1116 TD
[(determining)-309.8(whether)-310.5(there)-307.4(is)-301.6(a)-307.5(correlation)-309.7(between)-305.9(high)-304(se-)]TJ
T*
[(rum)-281(cholesterol)-286.5(and)-280.9(GO.)]TJ
1.0137 -1.1174 TD
[(The)-184.2(primary)-188.7(outcome)-184.2(of)-186.5(the)-183.1(study)-184(was)-189.5(the)-183.1(relation)-184.3(between)]TJ
-1.0137 -1.1116 TD
[(the)-540.2(presence)-537.4(of)-537.8(GO)-533.8(and)-540.1(low-density)-538.4(lipoprotein)-537.9(\(LDL\)-)]TJ
T*
[(cholesterol.)-382.1(The)-380(secondary)-381.8(outcomes)-375.2(were)-381.9(the)-379(relation)-374.4(be-)]TJ
0 -1.1174 TD
[(tween)-285.3(GO)-280.4(severity)-287.6(or)-278.6(activity)-282.4(and)-280.9(LDL-cholesterol.)]TJ
/F8 1 Tf
8.9663 0 0 8.9663 59.7543 218.2676 Tm
(Methods)Tj
/F11 1 Tf
0 -1.8336 TD
[(Study)-338.6(design)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 185.3858 Tm
[(The)-224.5(study)-224.3(was)-224(aimed)-228.1(at)-222.4(assessing)-230.5(the)-223.5(relation)-224.6(between)-225.3(GO)]TJ
-1.0137 -1.1116 TD
[(and)-315.5(LDL-cholesterol)-322.9(in)-313.3(GD)-315(patients)-316.6(in)-313.4(a)-313.3(cross-sectional)-320.4(in-)]TJ
0 -1.1174 TD
[(vestigation.)-277.4(The)-276.4(research)-272.4(design)-278.4(entailed)-271.9(the)-275.3(inclusion)-276.2(of)-267.1(all)]TJ
0 -1.1116 TD
[(consecutive)-448.8(GD)-441.7(patients,)-446.7(with)-443.3(or)-439.9(without)-441(GO,)-445.1(who)-441.9(came)]TJ
T*
[(under)-352.2(the)-350.2(authors)-349.7(observation)-348.5(to)-347.9(receive)-352.3(radioiodine)-354.6(treat-)]TJ
0 -1.1174 TD
[(ment)-283.4(over)-282(a)-278.7(period)-284.3(of)-278.6(18)-284.4(consecutive)-281.8(months.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 59.7543 105.9023 Tm
(Setting)Tj
/F4 1 Tf
9.843 0 0 9.843 69.7323 89.4614 Tm
[(The)-506.8(study)-500.8(was)-506.2(performed)-503(in)-503.4(a)-503.4(tertiary)-506.8(referral)-507.6(center,)]TJ
-1.0137 -1.1174 TD
[(namely)-200.4(the)-194.7(GO)-194(Clinic)-193.5(of)-192.2(the)-194.7(Endocrinology)-195.5(Units)-196.5(I)-191.1(and)-194.5(II)-192.2(and)]TJ
0 -1.1116 TD
[(of)-319(the)-321.4(Ophthalmopathy)-319.8(Unit)-316.6(I)-317.8(o)0(f)-318.9(the)-315.6(University)-318.5(Hospit)-7.5(al)-314.5(of)]TJ
T*
[(Pisa,)-337.1(Italy.)-338.6(Patients)-339.5(were)-341.6(enrolled)-333.9(from)-339.6(January)-338.1(1,)-332.8(2016,)-336.1(to)]TJ
25.5097 67.9242 TD
.0118 Tc
[(J)5.1(une)-359.1(30)4.9(,)-360.3(2)-.8(0)4.9(17.)-360.2(P)5.1(a)-2(t)4.8(i)-.9(en)4.9(ts)-357.7(were)-364.8(n)4.9(o)-.8(t)-358(s)-.6(elected)-363.7(b)4.9(ut)-358(rat)4.8(h)-.8(er)-363.6(wer)5(e)]TJ
0 -1.1174 TD
.0116 Tc
[(i)4.6(n)-1(clud)4.7(ed)-363.9(b)4.7(y)-369.6(means)-363.7(o)-1(f)-363.8(c)3.6(ons)4.9(ecut)4.6(iv)4.7(e)-370.8(s)4.9(ampl)4.6(ing)4.7(.)-366.2(The)-365(a)-2.2(d)4.7(o)-1(p)4.7(t)-1.1(ed)]TJ
0 -1.1116 TD
.0114 Tc
[(i)4.4(n)-1.2(clus)4.7(io)4.5(n)-404.4(a)3.4(nd)-398.6(exclus)4.7(io)4.5(n)-404.4(c)3.4(ri)4.4(teria)-399.8(a)3.4(re)-399.8(repo)4.5(rted)-398.6(below.)-401(Data)]TJ
T*
.0104 Tc
[(were)-308.6(collected)-307.5(b)3.5(y)-307.5(E)2.4(.S.,)-304.1(B.M.,)-304(R)-3.2(.R.,)-304.1(and)-301.7(F)-2.1(.M.)-304(a)2.4(nd)-301.7(were)-302.9(re-)]TJ
T*
.0101 Tc
[(corde)-3.7(d)-330.8(in)-336.6(a)-332(d)-2.5(atabase)-3.7(.)-327.4(T)-3.7(h)3.2(e)-337.7(s)3.4(tu)]TJ
12.3027 0 TD
.0069 Tc
[(dy)-334(w)-6.6(a)-6.9(s)-333.8(n)-5.7(ot)-334.2(b)-5.7(l)-5.8(in)-5.7(de)-6.9(d.)-336.4(T)-6.9(h)0(e)-340.9(f).1(o)-5.7(l)-.1(-)]TJ
-12.3027 -1.1174 TD
.0115 Tc
[(l)4.5(o)-1.1(wing)-594.4(d)4.6(a)-2.3(t)4.5(a)-2.3(base)-595.5(v)4.6(a)-2.3(l)4.5(i)-1.2(dati)4.5(on)-594.4(pr)4.7(oced)4.6(ures)-594.2(w)-2(ere)-595.5(e)-2.3(mpl)4.5(o)-1.1(y)4.6(e)-2.3(d)4.6(:)]TJ
0 -1.1116 TD
.0087 Tc
[(allow)-4.8(e).7(d)-551.1(c)-5.1(ha)-5.1(ra)-5.1(cter)-551.1(c)-5.1(h)-3.9(ec)-5.1(ks,)-547.7(b)-3.9(at)]TJ
12.9824 0 TD
.007 Tc
[(c)-6.8(h)-552.8(to)-5.6(ta)-6.8(ls)-5.4(,)-555.1(m)-1.1(i)-5.7(s).3(s)-5.4(i)0(n)-5.6(g)-552.8(r)-5.6(e)-1(c)-6.8(o).1(r)-5.6(d).1(s)]TJ
-12.9824 -1.1116 TD
.0131 Tc
[(c)5.1(h).5(e)5.1(c)-.7(k)6.2(,)-364.7(ca)5.1(rd)6.2(in)6.2(ali)6.1(t).4(y)-362.4(c)5.1(he)5.1(ck)6.2(,)-364.7(d).5(i)6.1(g)]TJ
12.1299 0 TD
.01 Tc
[(its)-365.3(c)-3.8(he)-3.8(ck,)-362.1(c)-3.8(onsistency)-365.5(c)-3.8(h)3.1(e)-3.8(c)2(k,)]TJ
-12.1299 -1.1174 TD
.0119 Tc
[(con)5(t)-.8(ro)5(l)-444.3(t)-.8(o)5(t)-.8(als,)-440.8(cr)5.1(os)5.2(s-s)5.2(y)-.7(st)4.9(em)-439.7(con)5(s)-.5(i)4.9(s)-.5(tency)-444.2(c)-1.9(h)5(e)-1.9(ck,)-440.8(d)-.7(ata)-445.4(t)4.9(ype)]TJ
0 -1.1116 TD
[(check)4.9(,)-216.3(h)4.9(a)-2(s)5.1(h)-213.9(to)4.9(tals)5.1(,)-216.3(l)4.8(imit)-208.3(ch)4.9(eck,)-210.5(lo)4.9(gi)4.8(c)-215.1(c)3.8(heck,)-210.5(p)4.9(resen)4.9(c)-2(e)-209.3(c)-2(h)4.9(e)-2(ck,)]TJ
T*
.0117 Tc
[(r)4.9(a)-2.1(n)4.8(g)-.9(e)-318.9(c)-2.1(heck)4.8(,)-320(s)-.7(p)4.8(e)-2.1(ll)4.7(in)4.8(g)-323.5(a)3.7(nd)-317.7(grammar)-323.4(check,)-320(and)-317.7(u)-.9(n)4.8(i)-1(qu)4.8(en)4.8(es)5(s)]TJ
0 -1.1174 TD
.0084 Tc
[(chec)-5.4(k.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 310.8472 577.1337 Tm
0 Tc
(Participants)Tj
/F4 1 Tf
9.843 0 0 9.843 320.8251 560.7495 Tm
[(The)-397.3(inclusion)-397.2(criterion)-398.5(comprised)-405(a)-393.9(diagnosis)-402.6(of)-393.8(GD)-401.4(in)]TJ
-1.0137 -1.1174 TD
[(patients)-224.4(scheduled)-226.5(to)-221.2(undergo)-221.9(radioiodine)-222.2(treatment)-228.1(and)-223.3(who)]TJ
0 -1.1116 TD
[(consequently)-195.3(discontinued)-200.1(antithyroid)-198.1(medications)-195.6(for)-199.1(two)-194.4(to)]TJ
T*
[(three)-330.5(days.)-325.6(The)-334(exclusion)-329.1(criterion)-329.3(was)-333.5(earlier)-328.2(treatment)-337.5(of)]TJ
0 -1.1174 TD
[(hyperthyroidism)-307(by)-307.5(methods)-303.8(other)-306.3(than)-311(antithyroid)-307.5(medica-)]TJ
0 -1.1116 TD
[(tions,)-348.8(namely)-350.1(thyroidectomy)-352.3(or)-347.7(radioiodine.)-346.5(A)-347.5(total)-352.6(of)-347.8(250)]TJ
T*
[(consecutive)-523.7(patients)-518.2(who)-522.5(satised)-523.5(the)-517.2(inclusion)-523.9(criterion)]TJ
0 -1.1174 TD
[(without)-366.1(the)-367.5(exclusion)-369.4(criterion)-375.4(were)-370.4(enrolled)-368.5(in)-365.2(the)-367.5(period)]TJ
0 -1.1116 TD
[(reported)-281.9(above.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 310.8472 445.6062 Tm
(Outcomes)Tj
/F4 1 Tf
9.843 0 0 9.843 320.8251 429.1653 Tm
[(The)-282.1(primary)-286.6(outcome)-287.9(of)-284.4(the)-286.8(study)-281.9(was)-287.4(the)-286.8(observation)-290.9(of)]TJ
-1.0137 -1.1116 TD
[(a)-255.7(relation)-253.4(between)-259.9(the)-252.3(presence)-260.9(of)-255.6(GO)-251.6(and)-257.9(LDL-cholesterol.)]TJ
T*
[(The)-328.2(secondary)-330(outcomes)-329.1(were)-330.1(the)-327.1(observation)-331.3(of)-324.7(a)-330.6(relation)]TJ
0 -1.1174 TD
[(between)-352(GO)-355.3(severity)-356.8(or)-347.7(activity)-357.2(\(the)-351.2(clinical)-358.4(activity)-351.5(score)]TJ
0 -1.1116 TD
[([CAS]\))-307.8(and)-309.7(LDL-cholesterol.)-320.6(Concerning)-308.2(severity,)-314.1(both)-309.8(the)]TJ
T*
[(NOSPECS)-322.2(score)-318.6(and)-315.5(the)-321.4(classication)-324.2(proposed)-320.8(by)-313.2(the)-321.4(Eu-)]TJ
0 -1.1174 TD
[(ropean)-492.7(Group)-495.9(On)-492.6(Graves)-494.5(Orbitopathy)-498.3(\(EUGOGO\))-498.1(were)]TJ
0 -1.1116 TD
[(used)-345.2(\(2628\).)-345.1(NOSPECS)-345.3(stands)-347.3(for)-343.1(no)-342(GO)-343.8(signs)-345.1(\(N\),)-347.4(only)]TJ
T*
[(eyelid)-343.3(signs)-345.1(\(O\),)-341.6(soft)-344.1(tissue)-341.7(involvemen)-9.1(t)-341(\(S\),)-340.6(proptosis)-343.8(\(P\),)]TJ
0 -1.1174 TD
[(extraocular)-241.6(motility)-235.3(restriction)-239.3(\(E\),)-238.3(corneal)-241.7(involvement)-234.9(\(C\),)]TJ
0 -1.1116 TD
[(and)-384.6(sight)-385.7(loss)-384.3(\(S\),)-386.6(resulting)-385.6(in)-382.5(a)-388.2(numerical)-383.5(value,)-391.5(wherein)]TJ
T*
[(each)-307.4(progressive)-302.1(class)-307.1(corresponds)-307.7(to)-301.8(a)-307.5(number)-302.7(from)-305.1(1)-300.6(t)0(o)-301.8(6)]TJ
T*
[(\(26\).)-290(According)-295.4(to)-290.3(the)-286.8(EUGOGO)-294.4(classication,)-298.8(the)-292.6(severity)]TJ
0 -1.1174 TD
[(of)-497.5(GO)-499.3(was)-500.5(dened)-498.3(as)-498.5(mild,)-498.9(moderately)-499.8(severe,)-502.9(or)-497.5(sight)]TJ
0 -1.1116 TD
[(threatening)-373.1(\(28\).)-376.4(CAS)-373.7(was)-373.8(evaluated)-371.9(according)-376.4(to)-370.9(Mourits)]TJ
/F5 1 Tf
T*
[(et)-470(al)]TJ
/F4 1 Tf
1.9756 0 TD
[(.)-470(\(29,30\).)-468.4(Additional)-474.4(outcomes)-473.1(were:)-469.6(\(i\))-469.9(the)-471.1(relation)]TJ
-1.9756 -1.1174 TD
[(between)-536.3(the)-534.5(presence)-537.4(of)-532.1(GO)-533.8(and)-534.4(total)-531.2(cholesterol,)-537.6(high)]TJ
0 -1.1116 TD
[(density)-262.4(lipoprotein)-261.4(\(HDL\)-cholesterol,)-270.6(and)-257.9(triglycerides;)-267(\(ii\))]TJ
T*
[(the)-304.1(association)-309.3(between)-305.9(the)-309.9(presence)-307(of)-301.7(GO)-309.2(and)-304(high)-304(LDL-)]TJ
0 -1.1174 TD
[(cholesterol,)-238.1(high)-234.9(total)-237.4(cholesterol,)-243.8(low)-234.7(HDL-cholesterol,)-245.4(and)]TJ
0 -1.1116 TD
[(high)-286.8(triglycerides.)-298(In)-290.1(accordance)-294.4(with)-293.5(the)-286.8(recommendations)]TJ
T*
[(of)-370.8(th)20.7(e)-388.2(E)0(u)19.6(r)0(o)20.9(p)0(e)19.7(a)0(n)-377.7(S)0(o)21(c)0(i)19.5(e)0(t)19.5(y)-387(of)-370.8(Hy)20(pe)19.7(rt)15(en)19.7(si)20.9(on)-376.6(\(E)19.7(SH)20.1(\))-381.2(a)0(n)19.7(d)-387(of)-370.8(th)20.7(e)]TJ
0 -1.1174 TD
[(Eu)19.6(ro)20.9(pe)19.7(an)-233.7(So)21(ci)19.5(et)19.5(y)-243(o)0(f)-226.8(C)0(a)18.6(r)0(d)20.9(i)0(o)15(l)0(o)20.7(g)0(y)-226.8(\()0(E)19.7(S)0(C)20(\))-243(\(2)20.9(5\))20.9(,)-239.6(L)0(D)18.8(L)0(-)13.9(c)0(h)19.7(o)0(l)20.7(e)0(s)19.9(t)0(e)19.5(r)0(o)20.9(l)]TJ
0 -1.1116 TD
.0122 Tc
[(was)-253.6(c)4.2(ons)5.5(id)5.3(er)5.4(ed)-253.8(hi)5.2(gh)-253.8(i)5.2(n)-253.8(th)5.3(e)-255(presence)-255(o)-.4(f)-253.8(v)5.3(alu)5.3(e)-1.6(s)]TJ
/F6 1 Tf
19.0243 0 TD
0 Tc
()Tj
/F4 1 Tf
.5587 0 TD
.0119 Tc
[(11)5(5)-167.7(m)3.8(g/)4.9(dL;)]TJ
-19.583 -1.1116 TD
.007 Tc
[(to)-5.6(ta)-6.8(l)-437.7(c)-6.8(ho)-5.6(le)-6.8(st)-5.7(e)-6.8(r).2(o)-5.6(l)-437.7(wa)-6.8(s)-437.4(c)-6.8(on)-5.6(si)-5.7(de)-6.8(r)-5.6(e)-1(d)-437.6(h)-5.6(ig)-5.6(h)-437.6(w)-6.5(he)-6.8(n)]TJ
/F6 1 Tf
19.0243 0 TD
0 Tc
()Tj
/F4 1 Tf
.5587 0 TD
.0119 Tc
[(19)5(0)-167.7(m)3.8(g/)4.9(dL;)]TJ
-19.583 -1.1116 TD
.0116 Tc
[(HDL-chol)4.6(es)4.9(terol)-381.3(was)-386.7(c)3.6(ons)4.9(id)4.7(ered)-386.9(l)4.6(o)-1(w)-382(w)-1.9(h)4.7(e)-2.2(n)]TJ
/F6 1 Tf
18.6384 0 TD
0 Tc
()Tj
/F4 1 Tf
.5587 0 TD
.013 Tc
[(46)-160.9(mg)6.1(/d)6.1(L)-386.7(i)6(n)]TJ
-19.1971 -1.1174 TD
.0103 Tc
[(wome)-3.5(n)-555.2(a)2.3(nd)]TJ
/F6 1 Tf
5.5812 0 TD
0 Tc
()Tj
/F4 1 Tf
.5644 0 TD
.012 Tc
[(40)-161.9(mg/d)5.1(L)-554.7(i)5(n)-553.5(m)-1.8(en;)-547.9(a)-1.8(n)5.1(d)-553.5(tr)5.2(igl)5(y)-.6(cer)5.2(i)-.7(d)5.1(e)-1.8(s)-553.4(w)4.3(er)5.2(e)]TJ
-6.1456 -1.1116 TD
.0131 Tc
[(c)5.1(o).5(n)6.2(s).7(id)6.2(er)6.3(ed)-276(hi)6.1(gh)-276(w)5.4(h).5(e)5.1(n)]TJ
/F6 1 Tf
9.3134 0 TD
0 Tc
()Tj
/F4 1 Tf
.5587 0 TD
.0118 Tc
[(15)4.9(0)-167.8(m)3.7(g/)4.8(dL.)]TJ
-8.8584 -1.1116 TD
0 Tc
[(The)-351.2(presence)-358.8(of)-353.5(GO)-349.5(was)-356.5(established)-361.2(in)-347.9(any)-355.8(patient)-356(with)]TJ
-1.0137 -1.1174 TD
[(a)-365.1(NOSPECS)-368.3(class)]TJ
/F6 1 Tf
7.862 0 TD
()Tj
/F4 1 Tf
.5529 0 TD
[(2,)-367.4(namely)-367.4(who)-361.3(had)-367.3(at)-366.4(least)-365(one)-367.3(of)-365(the)]TJ
-8.4149 -1.1116 TD
[(following)-489.2(eye)-495.2(features:)-497.2(\(i\))-492.9(exophthalmometry)]TJ
/F6 1 Tf
19.7385 0 TD
()Tj
/F4 1 Tf
.5472 0 TD
[(17)-169.2(mm)-494.2(in)]TJ
-20.2857 -1.1116 TD
[(women)-383.2(and)]TJ
/F6 1 Tf
5.1549 0 TD
()Tj
/F4 1 Tf
.5529 0 TD
[(19)-169.2(mm)-379(in)-382.5(men,)-383.5(based)-382(on)-382.3(measurements)-388.7(con-)]TJ
-5.7079 -1.1174 TD
[(ducted)-210.6(for)-204.8(the)-206.2(normal)-210.7(population)-208.4(\(3135\);)-210.5(\(ii\))-206.2(eyelid)-210.8(aperture)]TJ
/F6 1 Tf
0 -1.1116 TD
()Tj
/F4 1 Tf
.5529 0 TD
[(9)-162.4(m)0(m)-390.6(\(36\);)-385.7(\(iii\))-386(CAS)]TJ
/F6 1 Tf
9.1637 0 TD
()Tj
/F4 1 Tf
.5529 0 TD
[(1/7;)-384.8(\(iv\))-384.6(presence)-393.4(of)-382.3(diplopia;)-391.7(\(v\))]TJ
-10.2696 -1.1116 TD
[(presence)-318.5(of)-319(corneal)-322.3(alterations;)-322.4(\(vi\))-315.5(presence)-318.5(of)-319(GO-related)]TJ
/F8 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(CHOLESTEROL)-341.4(AND)-337.2(GRAVES)-334.7(ORBITOPATHY)-30517.1(387)]TJ
ET
endstream
endobj
43 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(alterations)-344.2(of)-336.2(the)-338.7(fundi;)-340.9(and)-338.5(\(vii\))-339.8(reduction)-340.8(in)-336.4(visual)-341.9(acuity)]TJ
0 -1.1174 TD
[(that)-282.3(could)-283.3(be)-279.8(attributed)-284.5(to)-278.8(GO.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 62.022 692.2203 Tm
[(Sources)-334.8(of)-330.4(data)-339.3(and)-329.4(measurements)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 675.7794 Tm
[(All)-390.3(patients)-397.2(underwent)-399.1(an)-395(ophthalmological)-397.4(assessment,)]TJ
-1.0137 -1.1116 TD
[(which)-347.5(included)-345.5(the)-344.4(following)-345.2(procedures:)-349.5(\(i\))-343.2(exophthalmo-)]TJ
T*
[(metry;)-360.6(\(ii\))-361.7(measurement)-364.7(of)-365(eyelid)-360.5(aperture;)-364.9(\(iii\))-357.2(evaluation)]TJ
0 -1.1174 TD
[(of)-365(CAS;)-363.4(\(iv\))-361.6(assessment)-366.4(of)-365(diplopia;)-362.9(\(v\))-360.3(assessment)-372.2(of)-359.3(the)]TJ
0 -1.1116 TD
[(corneal)-305(status;)-302.6(\(vi\))-304(examination)-305.2(of)-301.7(the)-298.3(fundi;)-300.6(and)-304(\(vii\))-299.4(mea-)]TJ
T*
[(surement)-403.9(of)-399.6(visual)-405.3(acuity.)-404.3(The)-403.1(following)-402.8(blood)-397.3(tests)-404(were)]TJ
0 -1.1174 TD
[(performed:)-469.6(free)-461.7(thyroxine)-466.3(\(fT4\))-467.4(and)-465.2(free)-461.7(triiodothyronine)]TJ
0 -1.1116 TD
[(\(fT3;)-427.2(Vitros)-428(Immunodia)-7.9(gnostics,)-428(Raritan,)-429.4(NJ\);)-425.6(thyrotropin)]TJ
T*
[(\(T)19.7(SH)20.1(;)-231.6(I)0(m)19.6(m)0(u)19.6(l)0(i)14.8(t)0(e)-222.4(2)0(0)20.8(0)0(0)20.8(;)-231.6(Si)20.9(em)18.5(en)19.7(s)-231.3(H)0(e)18.8(a)0(l)19.5(t)0(h)15(c)0(a)18.5(r)0(e)19.7(,)-228.1(Gw)19.1(yn)15.1(ed)19.7(d,)-217.6(Un)14.2(it)20.6(ed)]TJ
0 -1.1174 TD
-.0196 Tc
[(K)-19.6(i).2(n)-19.6(g)1.2(d)-19.6(o)-4.5(m)-19.6(\))0(;)-556.5(a)-19.6(nt)-19.6(i-)-19.6(TS)-19.6(H)-552.4(r)-19.6(ec)-19.6(ep)-19.6(to)-19.6(r)-545.9(a)-19.6(nt)-19.6(ib)-19.6(od)-19.6(ie)-19.6(s)-546.9(\()-19.6(TR)-19.6(A)-6.4(b)-19.6(;)-546.1(B)-19.6(ra)-19.6(hm)-19.6(s,)]TJ
0 -1.1116 TD
0 Tc
[(Be)18.6(rl)20.7(in)15(,)-308.7(G)0(e)18.8(r)0(m)19.6(a)0(n)19.7(y)0(\))20.9(;)-312.2(to)20.7(ta)13.8(l)-306.5(c)0(h)19.7(o)0(l)14.9(e)0(s)19.9(t)0(e)19.6(r)0(o)20.9(l)-312.3(\(R)19.8(oc)19.7(he)19.7(,)-314.5(M)0(a)18.8(n)0(n)20.8(h)0(e)19.7(i)0(m)19.5(,)-308.7(Ge)13.1(r-)]TJ
T*
[(ma)18.4(ny)20.8(\);)-347.9(LD)18.8(L-)19.7(ch)19.7(ol)20.7(es)19.9(te)19.6(ro)15.1(l)-352.6(\()0(R)19.8(o)0(c)19.7(h)0(e)19.7(\))0(;)-347.9(H)0(D)19.1(L)0(-)19.7(c)0(h)19.7(o)0(l)20.7(e)0(s)14.1(t)0(e)19.5(r)0(o)20.9(l)-352.6(\(R)19.8(oc)19.7(he)13.9(\);)]TJ
T*
[(an)19.7(d)-364(t)0(r)15(i)0(g)20.7(l)0(y)20.7(c)0(e)18.5(r)0(i)20.7(d)0(e)19.7(s)-369.5(\(R)19.8(oc)19.7(he)19.7(\).)-355.8(Sm)19.8(ok)20.8(in)20.7(g)-364(h)0(a)19.7(b)0(i)14.9(t)0(s)20.9(,)-360.5(ph)15.1(ys)21(ic)19.6(al)-354.8(ac)18.5(ti)20.6(vi)14.9(ty)]TJ
0 -1.1174 TD
[(\(a)19.7(t)-335.3(l)0(e)13.8(a)0(s)19.9(t)-335.3(30)-324.7(mi)19.5(nu)20.8(te)19.6(s)-340.7(o)0(f)-324.7(e)0(x)19.7(e)0(r)19.7(c)0(i)19.5(s)0(e)-325.7(t)0(h)15(r)0(e)19.7(e)-336.3(ti)20.6(me)18.4(s)-335(a)-336.3(we)18.8(ek)19.7(\),)-327(di)20.7(et)13.8(ar)19.7(y)]TJ
0 -1.1116 TD
[(ha)19.7(bi)20.7(ts)-226.8(\(r)20.9(ou)20.8(gh)20.8(ly)-221.2(es)14.1(ti)20.6(ma)18.4(te)19.6(d)-231.5(d)0(a)19.7(i)0(l)20.6(y)-231.5(ca)18.5(lo)20.7(ri)15(es)-222(in)-221.2(th)20.7(e)-232.6(l)0(a)19.6(s)0(t)-221(t)0(h)15(r)0(e)19.7(e)-232.6(da)19.7(ys)21(\),)]TJ
T*
[(an)19.7(d)-260.3(a)0(l)19.5(c)0(o)13.9(h)0(o)20.8(l)-260.4(co)19.7(ns)21(um)19.6(pt)20.7(io)15(n)-260.3(\()0(a)19.7(t)-260.4(le)19.6(as)19.9(t)-260.4(5)0(0)-146.2(g)-260.3(of)-255.6(et)19.5(ha)19.7(no)20.8(l/)20.6(we)18.8(ek)19.7(\))-266(w)0(e)18.8(r)0(e)]TJ
0 -1.1174 TD
[(re)19.7(co)19.7(rd)15.1(ed)-164.6(in)-169.4(al)19.5(l)-179.8(p)0(a)19.7(t)0(i)14.8(e)0(n)19.7(t)0(s)20.9(.)-176.2(Th)19.6(e)-180.8(f)0(o)20.9(l)0(l)20.6(o)0(w)14.2(i)0(n)20.7(g)-179.6(co)19.7(nd)20.8(it)20.6(io)20.7(ns)-169(or)-169.2(tr)20.7(ea)18.5(tm)19.5(en)13.9(ts)]TJ
0 -1.1116 TD
[(th)20.7(at)-389.4(ca)18.5(n)-392.8(p)0(o)20.8(t)0(e)19.5(n)0(t)20.7(i)0(a)13.8(l)0(l)20.6(y)-392.8(af)19.7(fe)19.7(ct)-389.4(ch)19.7(ol)20.7(es)19.9(te)19.6(ro)15.1(l)-392.9(l)0(e)19.6(v)0(e)19.7(l)0(s)-388(w)0(e)18.8(r)0(e)-383.5(r)0(e)19.7(c)0(o)19.7(r)0(d)15.1(e)0(d)19.7(:)]TJ
T*
[(di)20.7(ab)19.7(et)13.8(es)19.9(,)-302.9(c)0(h)19.7(r)0(o)20.9(n)0(i)20.7(c)-307.5(re)19.7(na)19.7(l)-306.5(f)0(a)19.7(i)0(l)20.6(u)0(r)20.9(e)0(,)-293.7(a)0(n)19.7(d)-306.4(th)20.7(er)19.7(ap)19.7(y)-306.4(w)0(i)19.8(t)0(h)-296.1(s)0(t)20.9(a)0(t)19.6(i)0(n)20.7(s)0(,)-292.3(n)0(o)15.1(n)0(-)]TJ
0 -1.1174 TD
[(st)20.9(at)13.8(in)-399.7(li)20.6(pi)15(d-)20.9(lo)20.7(we)18.8(ri)20.7(ng)-405.4(me)18.4(di)20.7(ca)18.5(ti)20.6(on)15.1(s,)-401.8(or)-399.6(ot)14.9(he)19.7(r)-410(m)0(e)18.4(d)0(i)20.7(c)0(a)12.8(t)0(i)20.6(o)0(n)20.8(s)-415.6(th)20.7(at)]TJ
0 -1.1116 TD
[(co)19.7(ul)20.7(d)-202.7(a)0(f)14(f)0(e)19.7(c)0(t)-193.6(l)0(i)20.6(p)0(i)20.7(d)-202.7(le)19.6(ve)19.7(ls)15.1(,)-199.3(i)0(n)20.7(c)0(l)13.8(u)0(d)20.8(i)0(n)20.7(g)-202.7(es)19.9(tr)20.7(op)15.1(ro)20.9(ge)19.7(st)20.9(in)20.7(s,)]TJ
/F12 1 Tf
19.8595 0 TD
(b)Tj
/F4 1 Tf
.5414 0 TD
[(-b)20.9(lo)15(ck)19.7(er)19.7(s,)]TJ
-20.4009 -1.1116 TD
-.0199 Tc
[(a)-19.9(n)-.2(d)-291.7(t)-19.9(hi)-19.9(az)-19.9(id)-19.9(e)-282.4(d)-19.9(iu)-19.9(r)-4.8(e)-19.9(ti)-19.9(cs)-19.9(.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 62.022 423.7227 Tm
0 Tc
[(Potential)-339.1(bias)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 407.2818 Tm
[(The)-299.4(possible)-297.8(uctuations)-302.5(of)-301.7(lipid)-299.6(levels)-297(over)-299.3(time,)-304.2(due)-298.2(to)]TJ
-1.0137 -1.1174 TD
[(eating)-337.5(habits)-341.9(or)-336.2(seasonal)-340.3(variations,)-345.2(could)-335.1(constitute)-342(a)-336.3(pos-)]TJ
0 -1.1116 TD
[(sible)-191(drawback)-191.7(of)-192.2(this)-188.8(study,)-187.4(as)-187.5(the)-188.9(lipid)-190.2(prole)-192(was)-189.5(measured)]TJ
T*
[(only)-327.1(once)-329.3(initially.)-332.1(In)-324.7(order)-329.1(to)-330.6(overcome)-330.3(this)-327(possible)-332.4(bias,)]TJ
0 -1.1174 TD
[(patients)-293.6(were)-295.6(classied)-295.3(according)-295.7(to)-290.3(the)-292.6(month)-294.9(or)-290.2(season)-296.5(of)]TJ
0 -1.1116 TD
(enrollment.)Tj
1.0137 -1.1116 TD
[(As)-262.1(mentioned)-261.4(above,)-264.7(the)-263.8(study)-264.6(included)-259.1(patients)-264.8(with)-264.7(GD)]TJ
-1.0137 -1.1174 TD
[(who)-315.2(came)-320.1(under)-317.7(the)-315.6(authors)-315.1(observation)-319.7(to)-313.4(undergo)-319.9(radio-)]TJ
0 -1.1116 TD
[(iodine)-359.4(treatment.)-358.2(The)-357(objective)-359.4(of)-353.5(this)-355.8(stratication)-363.6(was)-356.5(to)]TJ
T*
[(have)-352.3(two)-344.1(distinct)-350.1(groups)-346.2(of)-347.7(patients)-351.2(under)-352.2(the)-344.4(same)-353.3(condi-)]TJ
T*
[(tions,)-406.4(namely)-407.7(off)-406.4(antithyroid)-411.2(medications)-408.7(for)-406.4(two)-407.5(to)-405.5(three)]TJ
0 -1.1174 TD
[(days,)-423.5(therefore)-428.1(minimizin)-8.3(g)-421.6(the)-425.1(effects)-425.8(of)-428.4(thyroid)-422.6(function)]TJ
0 -1.1116 TD
[(changes)-356.6(on)-353.5(cholesterol)-355.6(levels,)-358(since)-353.3(both)-355.9(hyper-)-353.3(and)-350(hypo-)]TJ
T*
[(thyroidism)-283.1(affect)-286.6(cholesterol)-280.7(\(37\).)]TJ
1.0137 -1.1174 TD
.0131 Tc
[(As)-604.1(re)-6.4(po)-5.3(rte)-6.4(d)-598.5(b)-5.3(e)-.7(l)-5.4(o).5(w,)-606.6(a)-599.7(m)-.7(i)-5.4(n).5(o)-5.3(r).5(i)-5.4(t).4(y)-598.5(o)-5.3(f)-598.5(G)-6.1(O)-599.4(p)-5.3(at)-5.4(ien)-5.3(t).4(s)-604.1(h).5(a)-6.4(d)]TJ
-1.0137 -1.1116 TD
.0149 Tc
[(been)-326(subje)-4.6(c)1.1(te)-4.6(d)-326(t)2.2(o)-331.8(t)2.2(reatments)]TJ
12.343 0 TD
[(tha)-4.6(t)-326.1(could)-326(h)2.3(a)-4.6(v)2.3(e)-327.2(a)-4.6(ffected)-326(G)-4.3(O)]TJ
-12.343 -1.1116 TD
.0146 Tc
[(seve)-4.9(rity)-263(and)-263(activity.)-259.5(T)-5(h)2(e)-4.9(r)2(ef)]TJ
11.7498 0 TD
.0153 Tc
[(ore,)-264.6(in)-262.3(addition)-262.3(t)2.6(o)-262.3(t)2.6(he)-263.4(ana)-4.2(l)2.6(ysis)]TJ
-11.7498 -1.1174 TD
.013 Tc
[(o)-5.4(f)-350.9(the)-352.1(t)-5.5(ot)-5.5(al)-351.1(c)-6.5(oho)-5.4(rt)-351.1(o)-5.4(f)-350.9(GO)-351.8(p)-5.4(a)-.8(t)-5.5(i).3(en)]TJ
13.6332 0 TD
.0151 Tc
[(ts,)-345.4(s)-3.1(eparate)-350(d)-3.3(ata)-350(a)1.3(nalyse)-4.4(s)]TJ
-13.6332 -1.1116 TD
.0128 Tc
[(we)-6.7(re)-196.8(pe)-6.7(rf)-5.5(orm)-6.8(ed)-195.6(in)-189.9(t)-5.7(h).2(e)-196.8(s).4(u)-5.6(bgr)-5.5(ou)-5.6(p)-189.9(o)-5.6(f)-189.9(G)-6.4(O)-190.8(p).2(a)-6.7(t).1(i)-5.7(e)-1(nt)-5.7(s)-189.7(w)-6.4(ho)-195.6(ha)-6.7(d)-189.9(n).2(o)-5.6(t)]TJ
T*
.015 Tc
[(rece)-4.5(ived)-279.8(trea)-4.5(tme)-4.5(n)2.4(t.)]TJ
1.0137 -1.1174 TD
0 Tc
[(In)-290.1(theory,)-293.5(patients)-293.6(may)-293.7(have)-294.7(been)-289(affected)-301.5(by)-290.2(orbital)-291.5(dis-)]TJ
-1.0137 -1.1116 TD
[(eases)-423.3(distinct)-419.2(from)-414.5(GO)-418.6(but)-418.1(bearing)-419.1(a)-417(certain)-420.4(resemblance)]TJ
T*
[(to)-221.2(it,)-219(namely)-223.4(ocular)-222.1(myasthenia)-223.2(gravis)-220.8(or)-221(myositis)-223.2(\(27,38\).)-220.8(In)]TJ
T*
[(the)-327.1(latter)-331.8(cases,)-334.6(an)-325.9(isolated)-333.9(diplopia)-327.1(and/or)-330.4(palpebral)-330.4(ptosis)]TJ
0 -1.1174 TD
[(would)-225.4(have)-225.6(been)-225.6(expected,)-230.1(but)-228.1(none)-224.4(of)-221(the)-229.2(patients)-224.4(exhibited)]TJ
0 -1.1116 TD
[(these)-324.5(attributes.)-328.1(Other)-324.4(conditions)-323.4(that)-328.4(can)-322.4(resemble)-330.2(GO)-320.7(are)]TJ
T*
[(orbital)-377.9(lymphoma)-375.4(or)-376.5(inammatory)-379.8(orbital)-372.1(pseudotumor)-8.7(,)-372(i)0(n)]TJ
0 -1.1174 TD
[(which)-520.3(the)-517.2(ndings)-520.1(commonly)-513.7(differ)-520.4(from)-518.2(GO)-516.6(at)-521.9(orbital)]TJ
0 -1.1116 TD
[(computed)-248.7(tomography)-243.9(\(CT\))-248.5(or)-244.1(magnetic)-249.9(resonance)-250.5(imaging,)]TJ
T*
[(and)-211.8(hyperthyroidism)-209.1(is)-209.5(absent)-210.5(\(27,39\).)-209.2(A)-209.3(C)0(T)-211.8(scan)-208.1(of)-209.5(the)-206.2(orbit)]TJ
0 -1.1174 TD
[(was)-310.4(performed)-312.9(in)-313.3(84/133)-306.2(patients)-316.6(with)-310.8(an)-308.6(eye)-310.9(involvement,)]TJ
0 -1.1116 TD
[(and)-217.6(it)-221.3(revealed)-220.9(alterations)-229(typical)-217.8(to)-221.2(GO)-217(across)-221.6(all)-223.6(cases)-221.7(\(27\).)]TJ
T*
[(In)-434.1(addition,)-440(none)-437.5(of)-434.1(the)-436.6(patients)-437.5(displayed)-438.5(a)-434.2(reduction)-438.7(in)]TJ
25.504 67.9242 TD
[(vi)14.9(su)21(al)-176.3(ac)18.5(ui)20.7(ty)-175.1(in)-169.4(th)15(e)-180.8(a)0(b)19.7(s)0(e)14.1(n)0(c)19.7(e)-180.8(of)-175(ot)20.7(he)19.7(r)-185.4(G)0(O)-176.7(s)0(y)21(m)0(p)19.6(t)0(o)20.7(m)0(s)19.8(,)-187.7(al)19.5(l)-185.5(p)0(a)19.7(t)0(i)20.6(e)0(n)19.7(t)0(s)]TJ
0 -1.1174 TD
[(ob)15.1(ta)19.6(in)20.7(ed)-475.7(a)-480.3(c)0(l)19.5(e)0(a)18.5(r)0(-)15.1(c)0(u)19.7(t)-479.3(di)14.9(ag)19.7(no)20.8(si)20.9(s)-484.7(o)0(f)-474.5(G)0(r)20(a)0(v)19.7(e)0(s)19.9()-484.9(hy)20.8(pe)19.7(rt)20.7(hy)15.1(ro)20.9(id)20.7(is)20.9(m)]TJ
0 -1.1116 TD
[(wi)14.1(th)-284.5(de)19.7(te)13.8(ct)19.5(ab)19.7(le)-291.5(TR)18.6(Ab)20(,)-297.2(a)0(n)19.7(d)-300.6(th)20.7(e)-296(o)0(n)15.1(s)0(e)19.9(t)-295(of)-290.1(hy)20.8(pe)19.7(rt)15(hy)20.8(ro)20.9(id)20.7(is)15.1(m)-296.1(a)0(n)19.7(d)]TJ
T*
[(GO)-245.8(oc)19.7(cu)19.7(rr)20.9(ed)-239.5(wi)19.8(th)15(in)-238.5(si)20.9(x)-248.8(m)0(o)19.6(n)0(t)20.7(h)0(s)-243.9(f)0(r)20.9(o)0(m)-239.6(o)0(n)20.8(e)-249.9(an)19.7(ot)20.7(he)13.9(r)-248.7(i)0(n)-238.5(a)0(l)19.6(l)-248.9(ca)18.5(se)19.9(s,)]TJ
T*
[(as)-245.1(re)14(po)20.8(rt)20.7(ed)-245.3(pr)20.9(ev)19.7(io)20.7(us)15.3(ly)-244.2(in)-244.2(ty)20.7(pi)20.7(ca)18.5(l)-254.7(c)0(a)18.5(s)0(e)19.9(s)-254.3(of)-244.1(GO)-245.8(\(4)20.9(0\))20.9(.)-256.9(T)0(h)19.6(e)0(r)19.7(e)0(f)19.7(o)0(r)15.1(e)0(,)]TJ
0 -1.1174 TD
[(th)15(e)-261.4(p)0(o)20.8(s)0(s)21.2(i)0(b)20.7(i)0(l)14.8(i)0(t)20.6(y)-260.3(of)-249.8(mi)19.5(sd)21(ia)19.6(gn)20.8(os)15.3(is)-249.8(of)-249.8(or)20.9(bi)20.7(to)15(pa)19.7(th)20.7(ie)19.6(s)-260.1(d)0(i)20.7(f)0(f)15.1(e)0(r)19.7(e)0(n)19.7(t)-260.4(fr)20.9(om)]TJ
0 -1.1116 TD
[(GO)-263.1(wa)18.8(s)-271.6(h)0(i)20.7(g)0(h)15.1(l)0(y)-255.7(i)0(m)19.5(p)0(r)15.1(o)0(b)20.8(a)0(b)19.7(l)0(e)19.6(.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 313.0582 637.455 Tm
[(Sample)-338.6(size)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 621.014 Tm
[(Since,)-310.7(to)-307.6(the)-309.9(authors)-309.4(knowledge,)-310.4(there)-307.4(were)-307.1(no)-307.5(previous)]TJ
-1.0137 -1.1116 TD
[(studie)-7.8(s)-346.5(o)0(n)-347.8(cholesterol)-355.6(levels)-354.6(and)-350(GO,)-347.2(an)-354.7(exact)-348.9(sample)-355.7(size)]TJ
T*
[(could)-352.4(not)-349(be)-348.9(calculated.)-354.7(Based)-354.3(on)-347.8(an)-348.9(extrapolation)-352.4(derived)]TJ
0 -1.1174 TD
[(from)-212.9(the)-211.9(study)-207(of)-209.5(Stein)]TJ
/F5 1 Tf
9.2904 0 TD
[(et)-210.8(al)]TJ
/F4 1 Tf
1.7164 0 TD
[(.,)-208.4(namely,)-215.3(the)-206.2(assumption)-214.9(that)-213.2(the)]TJ
-11.0068 -1.1116 TD
[(protective)-199.2(effect)-200.2(of)-198(statins)-193.2(on)-198(GO)-194(development)-201.4(was)-195.2(due)-194.5(to)-198.2(the)]TJ
T*
[(lowering)-281.8(of)-272.9(cholesterol)-280.7(levels,)-277.4(and)-280.9(with)-276.2(the)-275.3(observation)-279.4(of)-272.9(a)]TJ
0 -1.1174 TD
[(40%)-286.6(GO)-286.2(reduction)-288.9(in)-284.6(patients)-287.8(treated)-287.9(with)-287.8(statins)-291.1(compared)]TJ
0 -1.1116 TD
[(to)-319.1(GD)-309.2(patients)-322.4(who)-309.4(were)-318.6(not)-314.5(given)-312.1(statins)-319.9(\(17\),)-313(it)-313.5(was)-316.2(esti-)]TJ
T*
[(mated)-251.1(that)-247.7(to)-244.2(obtain)-249.9(a)-244.2(statistically)-254.5(signicant)-249.5(difference)-251.8(with)]TJ
0 -1.1174 TD
(a)Tj
/F5 1 Tf
.7488 0 TD
(p)Tj
/F4 1 Tf
.5011 0 TD
[(-value)-297(of)]TJ
/F6 1 Tf
3.9396 0 TD
()Tj
/F4 1 Tf
.5529 0 TD
[(0.05)-294.7(and)-298.2(a)-301.8(statistical)-298.2(power)-301.3(of)-301.7(0.8)-293.6(for)-297(the)-304.1(pri-)]TJ
-5.7424 -1.1116 TD
[(mary)-369.6(outcome,)-366.2(at)-366.4(least)-365(50)-365.1(patients)-368.4(per)-367.3(group)-362.6(would)-369.4(be)-360.5(re-)]TJ
T*
[(quired.)-616.1(As)-607.6(reported)-616(above,)-610.3(250)-608.1(patients)-616.1(were)-612.3(enrolled,)]TJ
0 -1.1174 TD
[(thereby)-286.6(largely)-281(exceeding)-285.4(this)-280.9(estimate.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 313.0582 467.603 Tm
[(Study)-338.6(registration,)-333.9(informed)-338.1(consent,)-327.3(and)-335.7(approval)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 451.1621 Tm
[(The)-190(study)-189.8(was)-183.7(registered)-193.1(at)-187.8(ClinicalTrials.gov)-195.5(\(registration)]TJ
-1.0137 -1.1174 TD
[(number:)-332.8(NCT02721992\).)-325(Signed)-330.3(informed)-328(consent)-326.8(was)-327.7(ob-)]TJ
0 -1.1116 TD
[(tained)-308.7(from)-299.3(all)-304.2(patients)-305.1(enrolled)-305.1(in)-301.8(the)-304.1(study.)-302.6(Given)-307.2(the)-298.3(ob-)]TJ
T*
[(servat)-8.8(ional)-277.6(nature)-285.5(of)-278.6(the)-281.1(study,)-279.6(approval)-287.7(was)-281.6(not)-279.9(required.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 313.0582 396.3401 Tm
[(Quantitative)-339(variables)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 379.8991 Tm
[(Numerical)-493.8(data)-490.7(with)-489.3(a)-486.1(normal)-492.9(distribution,)-489.4(which)-485.7(was)]TJ
-1.0137 -1.1116 TD
.0129 Tc
[(ass)6.2(e)-.9(s)6.2(s).5(ed)-495(u)6(s).5(in)6(g)-495(t).2(h)6(e)-496.2(Wi)5.9(lk)6(s)-494.9(S).4(hapi)5.9(ro)-495(t)5.9(e)-.9(st)5.9(,)-497.4(a)4.9(re)-496.2(pr)6.1(es)6.2(en)6(ted)-495(a)4.9(s)]TJ
0 -1.1174 TD
.0138 Tc
[(me)5.8(an)]TJ
/F6 1 Tf
2.3845 0 TD
0 Tc
()Tj
/F4 1 Tf
.7315 0 TD
.0123 Tc
[(st)5.3(an)5.4(dard)-363.2(devi)5.3(at)5.3(io)5.4(n)-368.9(\()]TJ
/F5 1 Tf
8.3804 0 TD
.0126 Tc
(SD)Tj
/F4 1 Tf
1.2383 0 TD
.0122 Tc
[(\).)-359.9(The)-364.4(r)5.4(emai)5.2(ni)5.2(ng)-363.3(n)5.3(u)-.4(meri)5.2(cal)]TJ
-12.7347 -1.1116 TD
[(dat)5.3(a)-220.3(ar)5.5(e)-220.3(present)5.3(ed)-219.2(as)-219(med)5.4(i)-.4(an)-219.2(and)-219.2(i)5.3(nterq)5.4(u)-.3(arti)5.3(le)-220.3(r)5.5(a)-1.5(ng)5.4(e.)-215.8(Cu)5.4(tof)5.5(f)]TJ
T*
.0116 Tc
[(val)4.6(u)-1(es)-231.2(were)-226.8(es)4.9(tabl)4.6(ish)4.7(e)-2.2(d)-225.6(w)-1.9(i)4.6(t)-1.1(h)-225.6(t)-1.1(he)-226.8(fo)4.7(ll)4.6(owing)-225.6(f)-1(o)4.7(r)-1(mul)4.6(a)-2.2(:)-231.5([)4.8(\(mean)]TJ
0 -1.1174 TD
.0118 Tc
[(val)4.8(u)-.8(es)-357.7(in)-357.9(t)4.8(h)-.8(e)-359.1(n)4.9(on-)5(af)5(fected)-357.9(po)4.9(pu)4.9(latio)4.9(n)]TJ
/F6 1 Tf
15.8795 0 TD
0 Tc
()Tj
/F5 1 Tf
.7257 0 TD
.0126 Tc
(SD)Tj
/F4 1 Tf
1.6012 0 TD
.0113 Tc
[(i)4.3(n)-358.4(th)4.4(e)-359.6(a)-2.5(f)4.5(f)-1.3(ected)]TJ
-18.2064 -1.1116 TD
.0129 Tc
[(pop)6(ul)5.9(at)5.9(ion)6(\))]TJ
/F6 1 Tf
5.0109 0 TD
0 Tc
(+)Tj
/F4 1 Tf
.8352 0 TD
.0097 Tc
[(\(me)-4.1(a)1.7(n)-273.6(v)-2.9(alue)-4.1(s)-273.4(i)-3(n)-273.6(t)2.7(he)-274.8(affe)-4.1(cte)-4.1(d)-273.6(popula)-4.1(tion)]TJ
/F6 1 Tf
16.49 0 TD
0 Tc
()Tj
/F5 1 Tf
.7315 0 TD
.0069 Tc
(SD)Tj
/F4 1 Tf
-23.0676 -1.1116 TD
.0128 Tc
[(in)-328.1(the)-329.3(n)5.9(on-)6(af)6(fect)5.8(ed)-328.1(po)5.9(pul)5.8(at)5.8(io)5.9(n\)])6(/\()]TJ
/F5 1 Tf
13.9673 0 TD
.0126 Tc
(SD)Tj
/F4 1 Tf
1.5724 0 TD
.012 Tc
[(in)-328.9(th)5.1(e)-335.8(a)4(ff)5.2(ected)-334.7(p)5.1(opu)5.1(-)]TJ
-15.5397 -1.1174 TD
.0133 Tc
[(lat)6.3(i).6(o)6.4(n)]TJ
/F6 1 Tf
2.6322 0 TD
0 Tc
(+)Tj
/F5 1 Tf
.8467 0 TD
.0069 Tc
(SD)Tj
/F4 1 Tf
1.5148 0 TD
.012 Tc
[(in)-277.1(th)5.1(e)-278.2(n)-.6(o)5.1(n-aff)5.2(ected)-277.1(p)5.1(op)5.1(ulati)5(o)-.6(n)5.1(\))-.6(.)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 313.0582 270.3117 Tm
0 Tc
[(Statistical)-342.4(analyses)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 253.8708 Tm
[(When)-261.3(appropriate,)-261.1(the)-258(following)-258.8(tests)-260(were)-261(performed:)-256.5(\(i\))]TJ
/F5 1 Tf
-1.0137 -1.1174 TD
(t)Tj
/F4 1 Tf
.2822 0 TD
[(-test;)-192.2(\(ii\))-183.1(MannWhitney)]TJ
/F5 1 Tf
10.091 0 TD
(U)Tj
/F4 1 Tf
.72 0 TD
[(-test;)-186.5(\(iii\))-190.1(chi-square)-187.2(test;)-191.2(and)-188.8(\(iv\))]TJ
-11.0932 -1.1116 TD
[(multiple)-288.2(regression)-283.7(analysis.)]TJ
/F8 1 Tf
8.9663 0 0 8.9663 313.0582 209.9905 Tm
(Results)Tj
/F11 1 Tf
0 -1.8336 TD
(Participants)Tj
/F4 1 Tf
9.843 0 0 9.843 323.0361 177.1086 Tm
[(As)-371.5(shown)-369(in)-365.2(Table)-372(1,)-367.4(117)-366.2(patients)-368.4(without)-371.8(GO)-366.8(and)-373.1(133)]TJ
-1.0137 -1.1116 TD
[(patients)-270.5(with)-259(GO)-263.1(were)-266.8(examined.)-264.8(The)-264.9(proportion)-258.9(of)-261.4(patients)]TJ
T*
[(with)-351.1(GO)-349.5(was)-350.7(higher)-353.5(compared)-347.6(to)-347.9(that)-351.4(reported)-351(in)-347.9(previous)]TJ
0 -1.1174 TD
[(studie)-7.8(s)-191(\(1\).)-196.7(This)-195.6(reects)-201(the)-194.7(fact)-196.9(that)-195.9(the)-200.4(study)-195.5(was)-195.2(carried)-201.3(out)]TJ
0 -1.1116 TD
[(in)-290.3(a)-284.5(tertiary)-293.7(referral)-288.8(center,)-290.1(since,)-293.4(compared)-290(to)-284.5(primary)-292.4(care)]TJ
T*
[(or)-267.1(secondary)-266.6(referral)-271.5(centers,)-268(a)-261.4(greater)-270.5(proportion)-264.6(of)-261.4(the)-263.8(GD)]TJ
0 -1.1174 TD
[(patients)-420.3(who)-418.9(usually)-412.1(come)-416.9(under)-421.3(the)-413.5(authors)-418.8(observation)]TJ
0 -1.1116 TD
[(also)-374.1(suffer)-370.3(from)-368.4(GO)-372.6(\(1\).)-369.5(The)-368.5(two)-367.2(groups)-369.2(\(patients)-375.3(with)-368.4(or)]TJ
T*
[(without)-256.6(GO\))-258.4(were)-255.2(similar)-257.9(in)-255.7(terms)-255.5(of)-255.6(sex,)-255.4(familial)-254.8(history)-255.4(of)]TJ
0 -1.1174 TD
[(hypercholes)-9.8(terolemia,)-508(extent)-510.3(of)-503.3(physical)-512.3(activity,)-504.7(alcohol)]TJ
0 -1.1116 TD
[(consumption,)-242.6(body)-234.8(mass)-236.8(index)-231.4(\(BMI\),)-241.2(proportion)-235.8(of)-232.5(patients)]TJ
T*
[(with)-241.7(conditions)-242.8(that)-242(could)-242.9(affect)-240.5(cholesterol)-246.2(levels)-239.4(\(diabetes,)]TJ
/F8 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(388)Tj
47.719 0 TD
[(SABINI)-335.9(ET)-338.7(AL.)]TJ
ET
endstream
endobj
48 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 59.7543 348.3779 Tm
0 0 0 rg
0 Tc
0 Tw
[(chronic)-332.7(liver)-329.4(failure\),)-331.5(proportion)-328(of)-324.7(patients)-333.9(taking)-324.8(medica-)]TJ
0 -1.1116 TD
[(tions)-345.4(that)-345.6(could)-346.6(affect)-344.2(cholesterol)-349.8(levels)-348.8(\(statins,)-341.7(non-statin)]TJ
0 -1.1174 TD
[(lipid-lowering)-599.8(medications,)-596.4(estrogens)-599.4(and)-592(progestins,)]TJ
/F12 1 Tf
23.4074 0 TD
(b)Tj
/F4 1 Tf
.5529 0 TD
(-)Tj
-23.9604 -1.1116 TD
[(blockers,)-325.5(thiazide)-318(diuretics\),)-322.2(serum)-318.7(fT4,)-318.9(fT3,)-318.9(and)-321.2(TSH,)-313.9(and)]TJ
T*
[(thyroid)-336.2(status.)-339.4(In)-336.2(contrast,)-342.9(age,)-337.4(smoking)-337.2(habits,)-333.8(duration)-338.5(of)]TJ
0 -1.1174 TD
[(hyperthyroidism)-358.9(\(time)-359.5(since)-353.3(the)-355.9(diagnosis)-356.5(of)-353.5(hyperthyroid-)]TJ
0 -1.1116 TD
[(ism\),)-331.5(and)-332.8(TRAb)-330.1(levels)-337.3(exhibited)-329.4(signicant)-335.9(differences)-333.4(be-)]TJ
T*
[(tween)-371.7(the)-373.2(two)-367.2(groups.)-366.9(Thus,)-371.7(GO)-366.8(patients)-374.2(were)-370.4(on)-365.1(average)]TJ
T*
[(older,)-424.9(and)-424.9(they)-420.4(tended)-423.8(to)-422.8(be)-418.1(more)-421.5(frequently)-428.2(smokers.)-422.1(In)]TJ
0 -1.1174 TD
[(addition,)-422.7(the)-419.3(duration)-424.9(of)-416.9(hyperthyroidism)-422.2(was)-425.6(shorter)-417.7(and)]TJ
0 -1.1116 TD
[(TRAb)-295.5(levels)-291.2(higher)-290.1(in)-284.6(patients)-293.6(with)-287.8(GO.)-289.6(It)-290.3(is)-290.1(worth)-288.7(empha-)]TJ
T*
[(sizing)-255.5(that)-247.7(only)-252.2(a)-249.9(minority)-252.3(of)-249.8(patients)-253.2(in)-250(each)-255.6(group)-247.4(suffered)]TJ
0 -1.1174 TD
.0221 Tc
[(fr)3.8(o)3.7(m)-538.9(co)3.7(nd)3.7(i)3.6(t)-2.2(i)3.6(o)3.7(ns)-531.7(or)-531.9(to)3.7(o)3.7(k)-537.7(med)3.7(i)-2.2(cati)3.6(o)3.7(ns)-531.7(th)3.7(at)-537.8(co)3.7(ul)3.6(d)-537.7(a)2.6(f)3.8(f)-2(ect)]TJ
0 -1.1116 TD
.0187 Tc
[(c)-6.6(hol)-5.6(este)-6.6(rol)-5.6(,)-267(incl)-5.6(udi)-5.6(ng)-264.6(s)-5.2(t).2(at)-5.6(ins)-5.2(.)-267(None)-271.5(of)-264.6(t)-5.6(h).3(e)-265.8(p)-5.4(ati)-5.6(e)-.8(nts)-270.2(w)-.5(as)-270.2(on)]TJ
25.5097 14.4741 TD
[(glu)-5.4(c)-.8(oco)-5.4(r).4(ti)-5.6(coi)-5.6(d).3(s)-396.9(a)-.8(t)-403(t).2(he)-398.3(t)-5.6(i).2(me)-398.3(of)-402.8(enro)-5.4(llm)-6.7(ent.)-399.4(Ho)-5.4(wev)-5.4(e)-.8(r,)-399.4(32/)]TJ
0 -1.1116 TD
.0196 Tc
[(133)-286.8(\(24%\))-281(G)-5.4(O)-281.9(p)1.2(a)-5.7(tie)-5.7(nts)-286.6(h)1.2(ad)-286.8(been)-286.8(treate)-5.7(d)-281(with)-281(intravenous)]TJ
0 -1.1174 TD
.0187 Tc
[(glu)-5.4(c)-.8(oco)-5.4(r).4(ti)-5.6(coi)-5.6(d).3(s)-218.3(p).3(r)-5.4(e)-.8(vi)-5.6(ous)-5.2(ly,)-220.9(m)-.9(or)-5.4(e)-219.7(t).2(h)-5.4(a)-.8(n)-218.5(t).2(h)-5.4(r).4(ee)-219.7(mo)-5.4(nth)-5.4(s)-218.3(be)-6.6(for)-5.4(e)]TJ
0 -1.1116 TD
.0205 Tc
(enrollment.)Tj
/F11 1 Tf
8.9663 0 0 8.9663 310.8472 288.0566 Tm
0 Tc
[(Primary)-333.5(outcome)-332.2(data:)-336.5(relation)-333.4(between)]TJ
0 -1.2203 TD
[(the)-334.8(presence)-333.1(of)-330.4(GO)-334.9(and)-329.4(serum)-334.6(lipids)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 260.674 Tm
[(As)-406.1(shown)-409.4(in)-411.3(Table)-406.6(2,)-407.7(serum)-410.9(levels)-412.2(of)-411.1(total)-410.2(cholesterol,)]TJ
-1.0137 -1.1174 TD
[(LDL-cholesterol,)-263(HDL-cholesterol,)-262.7(and)-257.9(triglycerides)-260(did)-256.9(not)]TJ
0 -1.1116 TD
[(show)-356.4(any)-350(difference)-361.3(between)-357.8(patients)-356.9(with)-356.9(or)-353.5(without)-354.6(GO.)]TJ
T*
[(Since)-503.1(the)-499.9(two)-499.6(groups)-501.7(differed)-500.7(in)-503.4(terms)-503.1(of)-497.5(age,)-504.4(smoking)]TJ
0 -1.1174 TD
[(habits,)-189.8(duration)-188.8(of)-192.2(hyperthyroidism,)-189.5(and)-188.8(TRAb,)-195.3(as)-187.5(mentioned)]TJ
0 -1.1116 TD
[(above,)-230.1(multivariate)-231.7(regression)-231.9(analyses)-230.9(were)-226.4(performed)-232.2(with)]TJ
ET
59.754 709.512 490.167 .22681 re
f
59.754 422.986 490.167 .22675 re
f
59.754 690.803 490.167 .28345 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 120.2456 725.1588 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(1.)Tj
/F9 1 Tf
1.2496 0 TD
[(Features)-331(of)]TJ
/F4 1 Tf
5.7701 0 TD
(250)Tj
/F9 1 Tf
1.8312 0 TD
[(Consecutive)-336.3(Patients)-331.2(with)-334.7(Graves)-335.5(Disease)-335.6(in)-337.3(Relation)]TJ
-1.0596 -1.0135 TD
[(to)-330(the)-332.4(Presence)-337(or)-330(Absence)-337(of)-337(GO)]TJ
/F5 1 Tf
-16.9359 -1.8427 TD
[(Feature)-22750.9(No)-337(GO)-10219.3(GO)]TJ
/F4 1 Tf
47.8881 0 TD
(p)Tj
-47.8881 -1.8946 TD
[(Number)-337.3(of)-336(patients)-18737.4(117)-10909.7(133)-5934.3(N/A)]TJ
0 -1.0135 TD
[(Age)-339(\(years\))-16887.4(45.0)]TJ
/F6 1 Tf
23.587 0 TD
()Tj
/F4 1 Tf
.7198 0 TD
[(13.3)-334.6(\(range)-330.8(1875\))-1963.8(51.8)]TJ
/F6 1 Tf
11.6898 0 TD
()Tj
/F4 1 Tf
.7198 0 TD
[(10.9)-328.8(\(range)-336.5(2475\))]TJ
/F6 1 Tf
9.7723 0 TD
(<)Tj
/F7 1 Tf
.5528 0 TD
(0.0001)Tj
/F4 1 Tf
-47.0416 -1.0135 TD
[(Sex)-20170.4(94)-336(women,)-334(23)-330.2(men)-4485.5(109)-331.2(women,)-339.7(24)-330.2(men)-3984.5(NS)]TJ
0 -1.0077 TD
[(Familial)-340.2(history)-335.3(of)-330.2(hypercholesterolemia)-5061.5(Yes:)-334.2(37;)-337.1(no:)-331.4(80)-6013.9(Yes:)-334.2(56;)-337.1(no:)-331.4(77)-6013.9(NS)]TJ
0 -1.0135 TD
[(Smoking)-336.3(habits)-15325(Nonsmokers:)-336.3(76)]TJ
21.6694 -1.0135 TD
[(Ex-smokers:)-336.7(13)]TJ
T*
[(Current)-337.5(smokers:)-332.6(28)]TJ
12.4097 2.027 TD
[(Nonsmokers:)-336.3(63)]TJ
0 -1.0135 TD
[(Ex-smokers:)-336.7(27)]TJ
T*
[(Current)-337.5(smokers:)-332.6(43)]TJ
/F7 1 Tf
12.4097 2.027 TD
(0.01)Tj
/F4 1 Tf
-46.4887 -3.0347 TD
[(Physical)-338.5(activity)-333.4(\()]TJ
/F6 1 Tf
7.417 0 TD
()Tj
/F4 1 Tf
.5528 0 TD
[(30)-336(minutes)-331.9(three)-335.7(times/week\))-1611.9(Yes:)-334.2(16;)-337.1(no:)-331.4(101)-5513.9(Yes:)-334.2(16;)-337.1(no:)-331.4(117)-5513.9(NS)]TJ
-7.9698 -1.0135 TD
[(Alcohol)-337.5(consumption)-335.9(\()]TJ
/F6 1 Tf
9.4095 0 TD
()Tj
/F4 1 Tf
.5528 0 TD
[(50)-163.2(g/week\))-7317.9(Yes:)-334.2(4;)-336.2(no:)-331.4(113)-6014.9(Yes:)-334.2(12;)-337.1(no:)-331.4(121)-5513.9(NS)]TJ
-9.9623 -1.0135 TD
[(BMI)-338.8(\(kg/m)]TJ
7.3837 0 0 6.5625 105.222 593.0644 Tm
(2)Tj
9.845 0 0 9.845 108.9071 588.6991 Tm
[(\))-16343.7(24.7)]TJ
/F6 1 Tf
18.5943 0 TD
()Tj
/F4 1 Tf
.7198 0 TD
[(4.6)-333.6(\(range)-336.5(16.353.4\))-959.1(25.4)]TJ
/F6 1 Tf
11.6898 0 TD
()Tj
/F4 1 Tf
.7198 0 TD
[(5.0)-333.6(\(range)-330.8(14.940.6\))-964.8(NS)]TJ
-36.7165 -1.0135 TD
[(Diabetes)-18163.4(Yes:)-334.2(2;)-336.2(no:)-331.4(115)-6014.9(Yes:)-334.2(4;)-336.2(no:)-331.4(129)-6014.9(NS)]TJ
0 -1.0077 TD
[(Chronic)-337.5(renal)-335.7(failure)-13139.1(Yes:)-334.2(1;)-336.2(no:)-331.4(116)-6014.9(Yes:)-334.2(2;)-336.2(no:)-331.4(131)-6014.9(NS)]TJ
0 -1.0135 TD
[(Treatment)-337.6(with)-339.1(statins)-12521.6(Yes:)-334.2(4;)-336.2(no:)-331.4(113)-6014.9(Yes:)-334.2(9;)-336.2(no:)-331.4(124)-6014.9(NS)]TJ
T*
[(Treatment)-337.6(with)-339.1(non-statin)-333.9(lipid-lowering)]TJ
.9962 -1.0135 TD
(medications)Tj
20.6732 1.0135 TD
[(Yes:)-334.2(2;)-336.2(no:)-331.4(115)-6014.9(Yes:)-334.2(4;)-336.2(no:)-331.4(129)-6014.9(NS)]TJ
-21.6694 -2.0213 TD
[(Treatment)-337.6(with)-339.1(estroprogestins)-9023.6(Yes:)-334.2(9;)-336.2(no:)-331.4(108)-6014.9(Yes:)-334.2(5;)-336.2(no:)-331.4(127)-6014.9(NS)]TJ
0 -1.0135 TD
[(Treatment)-337.6(with)-339.1(medications)-332.6(possibly)-336.2(affecting)]TJ
.9962 -1.0135 TD
[(cholesterol)-337.2(\()]TJ
/F12 1 Tf
5.0675 0 TD
(b)Tj
/F4 1 Tf
.5528 0 TD
[(-blockers,)-337.1(thiazide)-340.2(diuretics\))]TJ
15.0528 1.0135 TD
[(Yes:)-334.2(3;)-336.2(no:)-331.4(114)-6014.9(Yes:)-334.2(6;)-336.2(no:)-331.4(127)-6014.9(NS)]TJ
-21.6694 -2.0212 TD
[(Time)-335.9(since)-335.5(diagnosis)-338.3(of)-330.2(hyperthyroidism)-340(\(months\))-959.2(43)-336(\(IQR)-334(2273\))-5856.6(18)-336(\(IQR)-334(1137.2\))]TJ
/F6 1 Tf
46.4887 0 TD
(<)Tj
/F7 1 Tf
.5528 0 TD
(0.0001)Tj
/F4 1 Tf
-47.0416 -1.0135 TD
[(fT4)-338.1(\(ng/dL\))-330.7(NV:)-338.8(0.71.7)-11436.6(1.2)]TJ
/F6 1 Tf
23.086 0 TD
()Tj
/F4 1 Tf
.7198 0 TD
[(0.5)-333.6(\(range)-336.5(0.53.5\))-2460.1(1.1)]TJ
/F6 1 Tf
11.6898 0 TD
()Tj
/F4 1 Tf
.7198 0 TD
[(0.5)-333.6(\(range)-336.5(0.43.8\))-2460.1(NS)]TJ
-36.2155 -1.0135 TD
[(fT3)-338.1(\(pg/mL\))-331.9(NV:)-338.8(2.75.7)-11154.5(5.1)]TJ
/F6 1 Tf
23.086 0 TD
()Tj
/F4 1 Tf
.7198 0 TD
[(2.4)-333.6(\(range)-336.5(2.916.9\))-1960.1(4.8)]TJ
/F6 1 Tf
11.6898 0 TD
()Tj
/F4 1 Tf
.7198 0 TD
[(2.3)-333.6(\(range)-336.5(2.417.5\))-1960.1(NS)]TJ
-36.2155 -1.0135 TD
[(TSH)-338.8(\(IU/mL\))-332.7(NV:)-338.8(0.44)-11415(0.6)-333.6(\(IQR)-334(0.061.3\))-4609(0.8)-333.6(\(IQR)-334(0.011.9\))-4609(NS)]TJ
0 -1.0077 TD
[(Thyroid)-336.5(status)-15825.8(Hypothyroid:)-335.7(2)]TJ
21.6694 -1.0135 TD
[(Euthyroid:)-334.1(95)]TJ
T*
[(Hyperthyroid:)-337.9(20)]TJ
12.4097 2.027 TD
[(Hypothyroid:)-335.7(6)]TJ
0 -1.0135 TD
[(Euthyroid:)-334.1(107)]TJ
T*
[(Hyperthyroid:)-337.9(20)]TJ
12.4097 2.027 TD
(NS)Tj
-46.4887 -3.0405 TD
[(TRAb)-335.2(\(IU/L\))-336.3(NV:)]TJ
/F6 1 Tf
7.8374 0 TD
(<)Tj
/F4 1 Tf
.5471 0 TD
[(1.5)-12035(2.0)-166.6(IU/L)-334.4(\(IQR)-339.8(0.93.7\))-2989.8(3.2)-166.6(IU/L)-334.4(\(IQR)-334(1.28.0\))]TJ
/F7 1 Tf
38.1043 0 TD
(0.001)Tj
/F4 1 Tf
8.7511 0 0 8.7511 67.748 411.1936 Tm
[(Numerical)-332.3(values)-335.8(are)-334.3(reported)-332.2(as)-334.1(mean)]TJ
/F6 1 Tf
16.2089 0 TD
()Tj
/F5 1 Tf
.7191 0 TD
(SD)Tj
/F4 1 Tf
1.5483 0 TD
[(or)-333.1(median)-335(and)-334.5(IQR,)-332.8(as)-334.1(appropriate.)-331.3(Statistically)-334.1(signicant)-335(values)-335.8(are)-334.3(shown)-331.7(in)-333.3(bold.)]TJ
/F5 1 Tf
-18.4763 -1.0301 TD
(p-)Tj
/F4 1 Tf
.8357 0 TD
[(Values)-331.6(were)-335.4(obtained)-333.9(by)]TJ
/F5 1 Tf
10.5079 0 TD
(t)Tj
/F4 1 Tf
.285 0 TD
[(-test,)-335.8(chi-square)-329.5(test,)-338.4(or)-333.1(MannWhitney)]TJ
/F5 1 Tf
16.5781 0 TD
(U)Tj
/F4 1 Tf
.7191 0 TD
[(-test,)-335.8(as)-334.1(appropriate.)]TJ
-28.9259 -1.0236 TD
[(GO,)-555.5(Graves)-555.6(orbitopathy;)-550.8(NS,)-553.1(not)-558.9(signicant;)-552.8(BMI,)-554.5(body)-552.5(mass)-554.5(index;)-555.3(IQR,)-553.1(interquartile)-555.8(range;)-556.3(fT4,)-551(free)-558.4(thyroxine;)-554.4(fT3,)-551(free)]TJ
-.9134 -1.0236 TD
[(triiodothyronine;)-333.7(TSH,)-334.3(thyrotropin;)-327.9(TRAb,)-335.7(anti-TSH)-336(receptor)-333.4(autoantibodies;)]TJ
/F5 1 Tf
31.9513 0 TD
(SD)Tj
/F4 1 Tf
1.2179 0 TD
[(,)-333(standard)-332.1(deviation.)]TJ
ET
59.754 153.808 490.167 .22676 re
f
59.754 86.457 490.167 .22675 re
f
59.754 135.099 490.167 .28348 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 140.9385 169.4551 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(2.)Tj
/F9 1 Tf
1.2496 0 TD
[(Serum)-335.2(Lipids)-336.5(in)]TJ
/F4 1 Tf
7.2903 0 TD
(250)Tj
/F9 1 Tf
1.8312 0 TD
[(Consecutive)-336.3(Patients)-337(with)-334.7(Graves)-335.5(Disease)]TJ
-7.5495 -1.0135 TD
[(in)-337.3(Relation)-332.4(to)-335.8(the)-332.4(Presence)-331.2(or)-335.8(Absence)-331.2(of)-337(GO)]TJ
/F5 1 Tf
-14.0681 -1.8427 TD
[(Feature)-16733.3(No)-337(GO)-14371.2(GO)]TJ
/F4 1 Tf
48.9073 0 TD
(p)Tj
-48.9073 -1.8946 TD
[(Total)-335.9(cholesterol)-337.2(\(mg/dL\))-4863.9(190.8)]TJ
/F6 1 Tf
17.8227 0 TD
()Tj
/F4 1 Tf
.7141 0 TD
[(41.7)-334.6(\(range)-336.5(102307\))-4862.4(197.6)]TJ
/F6 1 Tf
16.0894 0 TD
()Tj
/F4 1 Tf
.7198 0 TD
[(36.9)-334.6(\(range)-336.5(84302\))-4861.4(NS)]TJ
-35.3459 -1.0135 TD
[(LDL-cholesterol)-344.3(\(mg/dL\))-5036.6(118.8)]TJ
/F6 1 Tf
17.8227 0 TD
()Tj
/F4 1 Tf
.7141 0 TD
[(34.4)-334.6(\(range)-336.5(57211\))-5362.4(125.8)]TJ
/F6 1 Tf
16.0894 0 TD
()Tj
/F4 1 Tf
.7198 0 TD
[(33.8)-334.6(\(range)-336.5(35212\))-4861.4(NS)]TJ
-35.3459 -1.0135 TD
[(HDL-cholesterol)-344(\(mg/dL\))-7628(62)-336(\(IQR)-334(5176\))-10008.5(63)-330.2(\(IQR)-339.8(5176\))-7307.8(NS)]TJ
T*
[(Triglycerides)-12375.7(76)-336(\(IQR)-334(5797.2\))-9005.1(83)-336(\(IQR)-334(61.7102\))-6685.4(NS)]TJ
8.7511 0 0 8.7511 67.748 74.6078 Tm
[(Numerical)-332.3(values)-335.8(are)-334.3(reported)-332.2(as)-334.1(mean)]TJ
/F6 1 Tf
16.2089 0 TD
()Tj
/F5 1 Tf
.7191 0 TD
(SD)Tj
/F4 1 Tf
1.5483 0 TD
[(or)-333.1(median)-335(and)-334.5(IQR,)-332.8(as)-334.1(appropriate.)]TJ
/F5 1 Tf
-18.4763 -1.0236 TD
(p-)Tj
/F4 1 Tf
.8357 0 TD
[(Values)-331.6(were)-335.4(obtained)-333.9(by)]TJ
/F5 1 Tf
10.5079 0 TD
(t)Tj
/F4 1 Tf
.285 0 TD
[(-test)-333.1(or)-333.1(MannWhitney)]TJ
/F5 1 Tf
9.8471 0 TD
(U)Tj
/F4 1 Tf
.7191 0 TD
[(-test,)-329.3(as)-334.1(appropriate.)]TJ
-22.1949 -1.0236 TD
[(LDL,)-330.6(low-density)-333.6(lipoprotein;)-335.8(HDL,)-330.2(high-density)-336.7(lipoprotein.)]TJ
/F8 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(CHOLESTEROL)-341.4(AND)-337.2(GRAVES)-334.7(ORBITOPATHY)-30517.1(389)]TJ
ET
endstream
endobj
54 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(correction)-268.1(for)-262.4(each)-267.1(of)-261.4(the)-263.8(above-mentioned)-270.3(variables.)-270.3(While)]TJ
0 -1.1174 TD
[(corrections)-372.7(for)-366.1(age,)-366.2(smoking,)-369.4(and)-361.6(TRAb)-370.4(did)-366.3(not)-366.3(affect)-367.3(the)]TJ
0 -1.1116 TD
[(ndings,)-373.8(correction)-377.6(for)-377.6(duration)-373.1(of)-370.8(hyperthyroidism)-381.9(did)-372(so)]TJ
T*
[(signicantly.)-433.8(Thus,)-429.3(there)-434.1(was)-431.4(a)-434.2(signicant)-428.1(correlation)-436.4(be-)]TJ
T*
[(tween)-193.1(the)-194.7(presence)-197.5(of)-192.2(GO)-194(and)-194.5(both)-188.8(total)-197.1(and)-188.8(LDL-cholesterol)]TJ
0 -1.1174 TD
[(when)-248.3(adjusted)-253.1(for)-245.1(duration)-246.3(of)-249.8(hyperthyroidism)-249.4(\()]TJ
/F5 1 Tf
19.462 0 TD
(p)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.01)-242.9(and)]TJ
/F5 1 Tf
-20.8501 -1.1116 TD
(p)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.02,)-280.9(respectively\).)]TJ
-.3744 -1.1116 TD
[(Based)-267.9(on)-261.4(the)-263.8(duration)-269.4(of)-261.4(hyperthyroidism)-266.7(in)-267.3(patients)-264.8(with)]TJ
-1.0137 -1.1174 TD
[(or)-272.9(without)-279.7(GO,)-278.1(a)-273(cutoff)-278.5(value)-278.7(was)-275.8(established)-280.6(at)-274.2(44)-272.9(months,)]TJ
0 -1.1116 TD
[(and)-252.1(the)-252.3(cohort)-249.8(was)-252.8(divided)-251(into)-252.3(two)-246.2(groups:)-255.3(one)-252.1(with)-247.4(a)-249.9(short)]TJ
T*
(\()Tj
/F6 1 Tf
.3341 0 TD
(<)Tj
/F4 1 Tf
.5529 0 TD
[(44)-186.5(months\))-187.4(and)-188.8(the)-183.1(other)-191.1(with)-184.1(a)-192.3(long)-183.1(\()]TJ
/F6 1 Tf
14.8543 0 TD
()Tj
/F4 1 Tf
.5529 0 TD
[(44)-186.5(months\))-187.4(duration)]TJ
-16.2942 -1.1174 TD
[(of)-295.9(hyperthyroidism.)-304.7(When)-295.8(the)-298.3(analysis)-299(was)-298.9(restricted)-302.6(to)-296.1(pa-)]TJ
0 -1.1116 TD
[(tients)-347.8(with)-345.4(a)-342.1(duration)-344.3(of)-347.7(hyperthyroidism)]TJ
/F6 1 Tf
17.2734 0 TD
(<)Tj
/F4 1 Tf
.5472 0 TD
[(44)-347.8(months)-341.8(\(165)]TJ
-17.8205 -1.1116 TD
[(patients:)-363.9(106)-360.4(with)-362.6(GO)-366.8(and)-361.6(59)-359.3(without)-366.1(GO\),)-359.8(both)-361.6(total)-364.2(and)]TJ
T*
[(LDL-cholesterol)-299.9(levels)-297(resulted)-293.4(to)-296.1(be)-291.3(signicantly)-297.9(higher)-295.9(in)]TJ
0 -1.1174 TD
[(patients)-391.5(with)-385.7(GO)-389.8(\(Fig.)-387.9(1A\),)-387.7(whereas)-392(HDL-cholesterol)-391.7(and)]TJ
0 -1.1116 TD
[(triglycerides)-513.4(did)-510.3(not)-510.3(differ)-508.9(between)-513.3(the)-511.4(two)-511.2(groups)-507.5(\(not)]TJ
T*
[(shown\).)-316(In)-313.2(contrast)-316.4(and)-309.7(as)-314.2(expected,)-316.5(when)-317.5(the)-309.9(analysis)-316.3(was)]TJ
0 -1.1174 TD
[(restricted)-366(to)-353.7(patients)-362.7(with)-362.6(duration)-361.5(of)-353.5(hyperthyroidism)]TJ
/F6 1 Tf
22.7393 0 TD
()Tj
/F4 1 Tf
.5529 0 TD
(44)Tj
-23.2923 -1.1116 TD
[(months)-243.9(\(85)-239.4(patients:)-243(27)-244.1(with)-241.7(GO)-240.1(and)-240.6(58)-238.3(without)-245.1(GO\),)-244.6(serum)]TJ
25.504 21.1554 TD
[(lipids)-398.5(did)-395.1(not)-395.1(exhibit)-400.9(differences)-402.5(between)-398.1(patients)-397.2(with)-397.2(or)]TJ
0 -1.1174 TD
[(without)-285.4(GO)-280.4(\(not)-281(shown\).)]TJ
1.0137 -1.1116 TD
[(In)-192.2(patients)-195.6(with)-195.6(a)-192.3(duration)-194.5(of)-192.2(hyperthyroidism)]TJ
/F6 1 Tf
18.3389 0 TD
(<)Tj
/F4 1 Tf
.5529 0 TD
[(44)-192.3(months,)]TJ
-19.9055 -1.1116 TD
[(based)-289.9(on)-284.4(the)-281.1(presence)-289.7(or)-284.4(absence)-282.9(of)-284.4(GO,)-283.8(cutoff)-290.1(values)-285.3(were)]TJ
T*
[(established)-326.6(for)-314.3(total)-318.1(and)-321.2(LDL-cholesterol)-322.9(at)-314.5(191)-170.3(mg/dL)-319.1(and)]TJ
0 -1.1174 TD
[(118.4)-169.1(mg/dL,)-218.8(respectively.)-223.1(Serum)-215.1(concentrations)-227.6(of)-215.3(total)-220.2(and)]TJ
0 -1.1116 TD
[(LDL-choles)-10.8(terol)-323.7(above)-330.4(these)-324.6(values)-331.4(were)-330.1(associated)-326.6(with)-328.1(a)]TJ
T*
[(signicantly)-332.5(increased)-325.5(risk)-326.8(of)-324.7(GO:)-327.7(total)-323.8(cholesterol)-326.8(relative)]TJ
0 -1.1174 TD
[(ri)15(sk)-186.3(\(R)14.1(R\))]TJ
/F6 1 Tf
3.8014 0 TD
(=)Tj
/F4 1 Tf
.7084 0 TD
[(1.)24.3(47)-192.3([c)19.7(on)20.8(d)15.2(en)19.7(ce)-188.8(in)20.7(te)19.6(rv)15.1(al)-187.8(\(C)19.8(I\))-192.2(1.)18.5(01)20.8(2)20.8(.1)18.5(4])20.9(,)]TJ
/F5 1 Tf
16.4267 0 TD
(p)Tj
/F6 1 Tf
.6566 0 TD
(=)Tj
/F4 1 Tf
.7084 0 TD
[(0.)18.5(03)20.8(;)]TJ
-22.3016 -1.1116 TD
[(LD)13(L-)19.7(ch)19.7(ol)20.7(es)19.9(te)19.6(ro)15.1(l)-289.2(R)0(R)]TJ
/F6 1 Tf
8.3228 0 TD
(=)Tj
/F4 1 Tf
.7084 0 TD
[(1.)18.5(28)-278.7([C)14.1(I)-289(1)0(.)18.5(0)0(1)20.8()0(1)20.8(.)0(6)18.5(2)0(])20.9(,)]TJ
/F5 1 Tf
8.3919 0 TD
(p)Tj
/F6 1 Tf
.6566 0 TD
(=)Tj
/F4 1 Tf
.7084 0 TD
[(0.)18.5(03)20.8(.)-291.4(T)0(h)19.6(e)-296(fr)20.9(e-)]TJ
-18.7882 -1.1116 TD
[(qu)15.1(en)19.7(cy)-412.3(of)-416.9(GO)-412.9(ac)12.8(co)19.7(rd)20.9(in)20.7(g)-427.3(t)0(o)-411.3(t)0(h)20.7(e)-428.5(pr)20.9(es)19.9(en)19.7(ce)-419.2(of)-416.9(to)20.7(ta)19.6(l)-421.7(o)0(r)-416.9(L)0(D)18.8(L)0(-)]TJ
0 -1.1174 TD
[(ch)13.9(ol)20.7(es)19.9(te)19.6(ro)20.9(l)-179.8(c)0(o)13.9(n)0(c)19.7(e)0(n)19.7(t)0(r)20.7(a)0(t)19.5(i)0(o)20.7(n)0(s)-174.8(a)0(b)19.7(o)0(v)20.8(e)-180.8(th)20.7(e)-180.8(c)0(u)19.7(t)0(o)20.7(f)0(f)-174.9(v)0(a)19.7(l)0(u)20.7(e)0(s)-170.2(i)0(s)-169.2(i)0(l)20.6(l)0(u)14.9(s)0(t)20.9(r)0(a)19.7(t)0(e)19.5(d)]TJ
0 -1.1116 TD
[(in)-261.5(Fi)15.1(gu)20.8(re)-262.5(1B)19.8(.)]TJ
1.0137 -1.1116 TD
[(Subsequently,)-445.1(we)-442(analyzed)-445.6(the)-442.3(possible)-441.8(association)-441.8(be-)]TJ
-1.0137 -1.1116 TD
[(tween)-452.3(the)-448.1(presence)-451(of)-445.7(GO)-447.4(and)-448(the)-448.1(proportion)-449(of)-445.7(patients)]TJ
0 -1.1174 TD
[(with)-241.7(high)-240.7(LDL-cholesterol,)-245.7(high)-240.7(total)-243.2(cholesterol,)-243.8(low)-240.5(HDL-)]TJ
0 -1.1116 TD
[(chole)-8(sterol,)-339.5(and)-338.5(high)-338.6(triglycerides,)-344(all)-344.6(established)-343.9(in)-336.4(accor-)]TJ
T*
[(dance)-314.3(with)-310.8(the)-309.9(recommendations)-317.4(of)-307.4(ESH)-310.5(and)-309.7(ESC)-310.6(\(25\).)-307.3(As)]TJ
0 -1.1174 TD
[(demonstrated)-329(in)-324.9(Table)-325.9(3,)-327.1(the)-327.1(proportion)-322.2(of)-324.7(patients)-328.1(with)-322.3(an)]TJ
0 -1.1116 TD
[(alteration)-326(of)-324.7(the)-321.4(various)-319.8(serum)-324.5(lipid)-322.7(fractions)-323.3(did)-320.2(not)-320.2(differ)]TJ
T*
[(betwe)-8.8(en)-314.4(patients)-316.6(with)-322.3(and)-315.5(without)-320(GO.)-312.6(Howev)-8.4(er,)-312(when)-323.2(the)]TJ
0 -1.1174 TD
[(analy)-8(sis)-273.7(was)-270.1(restricted)-279.6(to)-273(the)-275.3(165)-274(patients)-276.3(with)-270.5(a)-273(duration)-275.1(of)]TJ
0 -1.1116 TD
(hyperthyroidism)Tj
/F6 1 Tf
6.8713 0 TD
(<)Tj
/F4 1 Tf
.5529 0 TD
[(44)-244.1(months,)-247.4(the)-246.5(proportion)-247.4(of)-249.8(patients)-247.5(with)]TJ
-7.4243 -1.1116 TD
[(high)-448(total)-444.8(cholesterol)-447.8(was)-442.9(signicantly)-447.7(greater)-449(in)-440.1(patients)]TJ
0 -1.1174 TD
[(with)-282(GO)-286.2(\(Table)-280.9(4\).)]TJ
/F11 1 Tf
8.9663 0 0 8.9663 313.0582 434.6645 Tm
[(Secondary)-337.3(outcome)-332.2(data:)-336.5(relation)-333.4(between)-331.9(GO)]TJ
0 -1.2203 TD
[(severity)-338.8(or)-329(activity)-339.1(and)-329.4(serum)-334.6(lipids)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 407.2818 Tm
[(Among)-439.6(patients)-437.6(with)-437.5(GO,)-439.4(both)-436.5(the)-436.6(NOSPECS)-437.4(score,)-437.3(a)]TJ
-1.0137 -1.1174 TD
[(measure)-398.1(of)-388.1(GO)-389.8(severity)-391.3(\(26\),)-387.9(and)-390.4(CAS,)-388.6(a)-388.2(measure)-392.3(of)-388.1(GO)]TJ
0 -1.1116 TD
[(activity)-288.1(\(29,30\),)-284.1(did)-285.7(not)-285.7(appear)-286.5(to)-278.8(correlate)-291.2(with)-282(serum)-289.9(con-)]TJ
T*
[(centrations)-660.9(of)-658.8(total)-657.9(cholesterol,)-658.5(LDL-cholesterol,)-666.2(HDL-)]TJ
0 -1.1174 TD
[(chole)-8(sterol,)-546.9(and)-551.6(triglycerides)-559.5(on)-549.4(univariate)-550.5(analysis)-558.2(\(not)]TJ
0 -1.1116 TD
[(shown\).)-362(This)-362.6(was)-356.5(also)-362.6(the)-355.9(case)-364.8(when)-357.8(GO)-361(severity)-362.5(was)-356.5(de-)]TJ
T*
[(termined)-208.4(using)-201.3(the)-200.4(EUGOGO)-208(classication)-203.3(\(28\))-200.2(\(not)-206.1(shown\).)]TJ
1.0137 -1.1174 TD
[(In)-272.9(the)-275.3(univariate)-279.8(analysis,)-273.6(the)-275.3(following)-276.1(variables)-278.4(showed)]TJ
-1.0137 -1.1116 TD
[(signicant)-307.1(correlations)-299.1(with)-299.3(NOSPECS:)-306.2(age)-299.4(\(direct)-298.2(correla-)]TJ
T*
(tion,)Tj
/F5 1 Tf
2.1023 0 TD
(p)Tj
/F6 1 Tf
.6624 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.005\);)-286.6(sex)-286.5(\(NOSPECS)-288.7(values)-285.3(3.6)]TJ
/F6 1 Tf
14.0249 0 TD
()Tj
/F4 1 Tf
.72 0 TD
[(1.0)-287.8(in)-284.6(men)-287.9(and)]TJ
-18.2295 -1.1116 TD
(3.1)Tj
/F6 1 Tf
1.4169 0 TD
()Tj
/F4 1 Tf
.72 0 TD
[(1.1)-374.2(in)-376.7(women;)]TJ
/F5 1 Tf
6.3818 0 TD
(p)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.04\),)-374.1(and)-373.1(TSH)-373.8(\(direct)-373.1(correlation)-10.2(,)]TJ
/F5 1 Tf
-9.9067 -1.1174 TD
(p)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.03\).)-316.5(Similar)-315.6(ndings)-318.5(were)-318.6(obtained)-316.7(when)-317.5(GO)-315(severity)]TJ
-1.3881 -1.1116 TD
[(was)-621.4(assessed)-616.3(according)-618.3(to)-612.9(the)-615.1(EUGOGO)-622.7(classication,)]TJ
T*
[(which)-318.7(in)-313.3(the)-309.9(univariate)-320.1(analysis)-310.5(also)-316.5(displayed)-317.6(a)-313.3(signicant)]TJ
0 -1.1174 TD
[(correlation)-390.3(with)-385.7(age)-380(\(direct)-384.6(correlation,)]TJ
/F5 1 Tf
16.6743 0 TD
(p)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.01\);)-383.4(sex)-378.6(\(GO)]TJ
-18.0624 -1.1116 TD
[(degree)-298(in)-290.3(men:)-294.9(mild)-293.9(4/24)-286.8([16.6%],)-296.7(moderately)-292.4(severe)-297.9(18/24)]TJ
T*
[([75%],)-269.1(sight)-270.5(threatening)-269.4(2/24)-269.5([8.4%];)-264.6(GO)-268.9(degree)-269.2(in)-267.3(women:)]TJ
0 -1.1174 TD
[(mild)-472.4(44/109)-467.5([40.4%],)-463.7(moderately)-471(severe)-470.6(59/109)-467.5([54.1%],)]TJ
0 -1.1116 TD
[(sight)-408.8(threatening)-407.6(6/109)-403.1([5.5%];)]TJ
/F5 1 Tf
13.4028 0 TD
(p)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.04\),)-402.9(and)-407.6(TSH)-402.6(\(direct)]TJ
-14.7909 -1.1116 TD
[(correlation)-10.2(,)]TJ
/F5 1 Tf
5.0801 0 TD
(p)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.01\).)-472(Although)-476.5(this)-476.8(did)-475.7(not)-475.7(constitute)-474.4(an)]TJ
-6.4681 -1.1174 TD
[(established)-476.4(aim)-472.4(of)-474.5(the)-471.1(present)-476.5(study,)-469.7(the)-471.1(former)-475.4(ndings)]TJ
0 -1.1116 TD
[(conrm)-279.5(the)-281.1(role)-276.4(of)-272.9(age,)-279.8(sex,)-278.4(and)-275.2(hypothyroidism)-281.8(as)-273.9(GO)-280.4(risk)]TJ
T*
[(factors)-223(\(4\).)-214(In)-215.3(the)-211.9(multivaria)-9.3(te)-210.8(analysis,)-221.8(adjustments)-217.3(for)-216.3(these)]TJ
T*
[(three)-215.3(variables)-209.3(did)-210.8(not)-205(show)-212.4(a)-209.6(signicant)-209.2(correlation)-211.8(between)]TJ
0 -1.1174 TD
[(GO)-412.9(severity)-420.1(\(assessed)-415.8(both)-407.7(using)-414.4(NOSPECS)-414.4(and)-413.4(the)-413.5(EU-)]TJ
0 -1.1116 TD
[(GOGO)-284.4(classication\))-290.7(and)-280.9(serum)-278.4(lipids.)]TJ
1.0137 -1.1116 TD
.0119 Tc
[(By)-409.7(mean)5(s)-415.2(o)-.7(f)-415.4(t)4.9(he)-410.8(uni)4.9(vari)4.9(at)4.9(e)-416.6(a)-1.9(n)5(a)-1.9(l)4.9(y)-.7(si)4.9(s,)-412(CAS)-415.2(d)5(isp)5(l)-.8(ayed)-415.4(a)]TJ
-1.0137 -1.1174 TD
.0122 Tc
[(sig)5.3(n)-.4(i)5.2()-.2(cant)-179.1(cor)5.4(r)-.4(el)5.2(at)5.2(io)5.3(n)-184.7(w)4.5(it)5.2(h)-179(a)-1.6(g)5.3(e)-185.9(\()5.4(d)-.4(i)5.2(r)-.4(ect)-179.1(c)-1.6(o)5.3(r)-.4(r)5.4(e)-1.6(lati)5.2(on)5.3(,)]TJ
/F5 1 Tf
20.5046 0 TD
0 Tc
(p)Tj
/F6 1 Tf
.6796 0 TD
(=)Tj
/F4 1 Tf
.7257 0 TD
.0119 Tc
[(0.0)5(1\),)]TJ
-21.9099 -1.1116 TD
[(fT4)-242.5(\()5.2(inv)5.1(e)-1.8(r)5.2(s)-.4(e)-243.7(c)-1.8(o)5.1(rrelati)5(on)5.1(,)]TJ
/F5 1 Tf
10.2523 0 TD
0 Tc
(p)Tj
/F6 1 Tf
.6796 0 TD
(=)Tj
/F4 1 Tf
.7257 0 TD
.0118 Tc
[(0.03)4.9(\),)-245.1(f)5(T)-2(3)-242.7(\()-.8(i)4.8(n)-.8(v)4.9(e)-2(r)5(s)-.6(e)-243.9(c)-2(o)4.9(rrelati)4.8(on)]TJ
/F5 1 Tf
12.3891 0 TD
0 Tc
(,)Tj
-24.0468 -1.1116 TD
(p)Tj
/F6 1 Tf
.6796 0 TD
(=)Tj
/F4 1 Tf
.7315 0 TD
.0125 Tc
[(0)5.6(.)3.3(04)5.6(\),)-428.7(and)-426.3(T)4.5(SH)-427.2(\(d)5.6(irect)-426.5(c)4.5(orr)5.7(el)5.5(at)5.5(io)5.6(n,)]TJ
/F5 1 Tf
15.3554 0 TD
0 Tc
(p)Tj
/F6 1 Tf
.6739 0 TD
(=)Tj
/F4 1 Tf
.7315 0 TD
.0072 Tc
[(0.)-7.7(00)-5.4(1\))-5.4(,)-434(f).4(u)-5.4(r).4(t)-5.5(h)-5.4(er)]TJ
-18.1719 -1.1174 TD
.0124 Tc
[(con)5.5()-.1(r)5.6(m)-1.4(i)5.4(n)-.2(g)-317(t)5.4(he)-312.4(rol)5.4(e)-318.2(o)5.5(f)-317(a)-1.4(g)5.5(e)-318.2(and)-317(h)5.5(yp)5.5(oth)5.5(y)-.2(r)5.6(o)-.2(i)5.4(d)-.2(is)5.7(m)-318.2(a)4.4(s)-316.8(G)-1.1(O)-312.1(r)-.2(i)5.4(s)0(k)]TJ
0 -1.1116 TD
.0116 Tc
[(facto)4.7(r)-1(s)-392.5(\(4\))4.8(.)-395(I)-1(n)-392.7(a)-2.2(d)4.7(d)-1(it)4.6(io)4.7(n,)-395(an)-398.4(i)4.6(n)-1(v)4.7(e)-2.2(rs)4.9(e)-399.6(c)3.6(or)4.8(relat)4.6(i)-1.1(o)4.7(n)-398.4(was)-392.5(d)-1(eter-)]TJ
T*
.0121 Tc
[(mi)5.1(ned)-253.9(b)5.2(etween)-259.7(CAS)-253.8(a)-1.7(n)5.2(d)-253.9(GO)-254.8(du)5.2(rat)5.1(i)-.6(o)5.2(n)-259.7(\()]TJ
/F5 1 Tf
16.3633 0 TD
0 Tc
(p)Tj
/F6 1 Tf
.6796 0 TD
(=)Tj
/F4 1 Tf
.7257 0 TD
.0118 Tc
[(0.02)4.9(\),)-256.6(r)5(e)-2()5.1(e)-2(ctin)4.9(g)]TJ
ET
q
1 i
62.589 480.189 m
300.529 480.189 l
300.529 173.027 l
62.589 173.027 l
W n
q
238.023 0 0 307.162 62.589 173.027 cm
/Im1 Do
Q
Q
BT
/F7 1 Tf
9.845 0 0 9.845 62.022 156.2456 Tm
0 Tc
[(FIG.)-578.6(1.)]TJ
/F4 1 Tf
4.3592 0 TD
(\()Tj
/F7 1 Tf
.334 0 TD
(A)Tj
/F4 1 Tf
.7198 0 TD
[(\))-576.8(Total)-577.7(and)-580(low-density)-577.6(lipoprotein)-582.9(\(LDL\)-)]TJ
-5.413 -1.0135 TD
[(cholesterol)-440.9(\(mean)]TJ
/F6 1 Tf
7.5207 0 TD
()Tj
/F4 1 Tf
.7141 0 TD
[(standard)-442.2(deviation\))-433.1(levels)-440.4(in)-434.1(165)-434.9(con-)]TJ
-8.2347 -1.0135 TD
[(secutive)-253.5(patients)-252.5(with)-247(Graves)-251.8(disease)-252.1(who)-251.4(had)-246(a)-249.8(duration)-251.3(of)]TJ
T*
[(hyperthyroidism)-374.6(\(time)-376.2(since)-370.1(the)-372.9(diagnosis\))]TJ
/F6 1 Tf
18.0127 0 TD
(<)Tj
/F4 1 Tf
.5528 0 TD
[(44)-370.5(months,)-373.3(in)]TJ
-18.5655 -1.0077 TD
[(relation)-425.4(to)-416.8(the)-418.9(presence)-427(\(106)-418.6(patients\))-426.2(or)-416.6(absence)-426.1(\(59)-417.6(pa-)]TJ
0 -1.0135 TD
[(tients\))-256.1(of)-255.4(Graves)-257.5(orbitopathy)-254.4(\(GO\).)]TJ
/F5 1 Tf
14.7591 0 TD
(p)Tj
/F4 1 Tf
.501 0 TD
[(-Values)-257.7(were)-254.7(obtained)]TJ
-15.2601 -1.0135 TD
(by)Tj
/F5 1 Tf
1.2726 0 TD
(t)Tj
/F4 1 Tf
.2822 0 TD
[(-test.)-274.6(\()]TJ
/F7 1 Tf
2.5798 0 TD
(B)Tj
/F4 1 Tf
.668 0 TD
[(\))-271.6(Frequency)-277.1(of)-272.6(GO)-268.5(in)-272.8(relation)-275.7(to)-272.8(the)-269.2(presence)-277.3(of)]TJ
-4.8026 -1.0077 TD
[(total)-507.6(or)-508.7(LDL-cholesterol)-517.1(serum)-508.1(concentrations)-514.1(above)-508.3(the)]TJ
0 -1.0135 TD
[(indicated)-300.9(cutoff)-301(values)-302(in)-301.6(165)-296.7(patients)-304.3(with)-298.8(Graves)-303.6(disease)]TJ
T*
[(who)-539.3(had)-533.9(a)-537.7(duration)-539.2(of)-531.8(hyperthyroidism)]TJ
/F6 1 Tf
17.6327 0 TD
(<)Tj
/F4 1 Tf
.5528 0 TD
[(44)-531.8(months.)]TJ
/F5 1 Tf
5.2691 0 TD
(p)Tj
/F4 1 Tf
.501 0 TD
(-)Tj
-23.9555 -1.0135 TD
[(Values)-337.3(were)-335.4(obtained)-333.1(by)-336(chi-square)-335.9(test.)]TJ
/F8 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(390)Tj
47.719 0 TD
[(SABINI)-335.9(ET)-338.7(AL.)]TJ
ET
endstream
endobj
56 0 obj
<>stream
Adobe d C
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz ? Ny_^ %Ɲo
y"TK0gRU>uee2 ͛6lO/8ei Urp*Cmc@I W[ Fo Fћu 4f']o j@I W[ Fo Fћu 4f']o j@I W[ Fo Fћu 4f']o j@I W[ Fo Fћu 4f']o j@I W[ Fo Fћu 4f']o j@I W[ Fo Fћu 4f']o j@I W[ Fo Fћu 4f']o j@I W[ Fo Fћu 4f']o j@I W[ Fo Fћu 4f']o j@I W[ Fo Fћu 4f']o j@I W[ Fo Fћu 4f']o j@I W[ Fo Fр>OӥT2Q]єj(Æ|͛! r_'~\k-;iw}x ?jZMΨ:[4S3D
yu9Oǟ96~S跒; G^Ե+wtٳf͛
5o
v/HԯxjMfNȍȸ*7`*G|ie5
6S %H^6 #l/lɵ99ǭxִ]B'[N!`C5:+Y8fI$2 ~}+KѵYٮi.yMʈח
,}MdE%Uv?⺶]$XجV^Ќ/ռѠiZy{V7(EP o4O:k7 [vrPTOvÅ{uK݈U:$ : h{z^ F JƗ<%A/T5.QZ(~X&["dYdXVf *שRWkB&b1ۋwr3iIt kV?Iݬ2ɹ GTIntDW7f)FJU*IP{˷:=dkɦizqZ)
c"T~
ڎP!*ȠU=[}im'gQCȚo-(-QtguPTR ;DuO#i^5>]+]L[YT1̆!]h$;p&62濱QG+
nAڠ\i8d7P
s"Cр
^d@0\g[m#*WgS.1|n3\j[N A"5nc"6ⓒӎiy,-F4+C/0B~%Rzr\ĒrTΡ>'vqo+HJ4MUVu=K3\u
yEKUe5h,71OfWR^4
|o,m_F1YHH$wj:= i^j5+B5j\(9:)%."{e)Ԡ֬
6Cum=} R^4S